Synaptic vesicle glycoprotein 2 (SV2) imaging agents and methods of using same
Novel radioligands like [18F]SDM-18 address the challenges of spinal cord PET imaging by providing high-resolution SV2A quantification, enhancing the accuracy and effectiveness of PET imaging for spinal cord pathophysiology assessment.
Patent Information
- Application Number
- PCT/US2026/027831
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-12
- Filing Date
- 2026-05-12
- Publication Date
- 2026-11-19
AI Technical Summary
Functional imaging of the spinal cord using PET is challenging due to its small size, lower protein density, and the relatively low spatial resolution of PET images, limiting the effectiveness of existing SV2A-specific radiotracers like [11C]UCB-J.
Development of novel radioligands, such as [18F]SDM-18, with structural modifications based on the pharmacophore of UCB-A and SDM-16, which exhibit improved brain kinetics and higher binding potential (BPND) for SV2A in both the brain and spinal cord, allowing for high-resolution PET imaging.
[18F]SDM-18 demonstrates higher BPND and stable Vt, enabling accurate quantification of SV2A in the spinal cord, with potential applications in monitoring spinal cord injury and diseases like ALS.
Smart Images

Figure US2026027831_19112026_PF_FP_ABST
Abstract
Description
[0001] Attorney Docket No. 047162-7570W01(02947)
[0002] TITLE OF THE INVENTION
[0003] Synaptic Vesicle Glycoprotein 2 (SV2) Imaging Agents and Methods of Using Same
[0004] CROSS-REFERENCE TO RELATED APPLICATIONS
[0005] This application claims priority under 35 U. S. C. § 119(e) to U. S. Provisional Patent Application No. 63 / 804,244. filed May 12, 2025, which is incorporated herein by reference in its entirety.
[0006] STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT
[0007] This invention was made with government support under NS 123183 awarded by National Institutes of Health. The government has certain rights in the invention.
[0008] BACKGROUND
[0009] The central nervous system (CNS), comprising the brain and spinal cord, plays a vital role in transmitting nerve signals that regulate critical bodily functions. While brain imaging has garnered more attention in the field of positron emission tomography (PET), there is growing interest in using this approach to explore in vivo molecular and functional imaging of the spinal cord. PET offers greater sensitivity compared to other imaging modalities like magnetic resonance imaging (MRI) or computed tomography (CT). However, functional imaging of the spinal cord using PET remains challenging due to its small size, lower protein density, and the relatively low spatial resolution of PET images.
[0010] There is thus a need in the art for compositions and methods for producing high resolution PET images of the spinal cord and / or brain. The present disclosure addresses this need.
[0011] BRIEF SUMMARY
[0012] In one aspect, the disclosure provides a compound of Formula (I), or a salt, solvate, tautomer, or stereoisomer thereof, or any mixtures thereof, wherein Rla, Rlb, Rlc, Rld, Rle, R2a, R2b. R2C. R2d. R2C. R3. and L are defined elsewhere herein:
[0013]
[0014] Attorney Docket No. 047162-7570W01(02947)
[0015] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (la), wherein R4a, R4b, and R4care defined elsewhere herein:
[0016]
[0017] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (lb), wherein R4a, R4b, and R4care defined elsewhere herein:
[0018]
[0019] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (Ic), wherein R4aand R4bare defined elsewhere herein:
[0020]
[0021] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (Id), wherein R4a, R4b, R4c, and R4dare defined elsewhere herein:
[0022]
[0023] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (le), wherein R4a, R4b, R4c, and R4dare defined elsewhere herein:
[0024]
[0025] Attorney Docket No. 047162-7570W01(02947)
[0026] In certain embodiments, the compound of Formula (I) is a compound a compound of
[0027] Formula (If-1):
[0028]
[0029] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (If-2):
[0030]
[0031] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (Ig), wherein R4a, R4b, and R4care defined elsewhere herein:
[0032]
[0033] In certain embodiments, the compound of Formula (I) is a compound a compound of Formula (Ih), wherein R4a, R4b, R4c, and R4dare defined elsewhere herein:
[0034]
[0035] In another aspect, the disclosure provides a pharmaceutical composition comprising a compound of the disclosure and at least one pharmaceutically acceptable carrier.
[0036] In another aspect, the disclosure provides a method for imaging or detecting a Synaptic Vesicle Protein 2 (SV2) in a subject. In certain embodiments, the method comprises:
[0037] administering to the subject at least one compound of the disclosure or the pharmaceutical composition of the disclosure; and
[0038] Attorney Docket No. 047162-7570W01(02947)
[0039] detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject.
[0040] In another aspect, the disclosure provides a method for quantifying a Synaptic Vesicle Protein 2 (SV2) in a subject. In certain embodiments, the method comprises:
[0041] administering to the subject at least one compound of the disclosure or the pharmaceutical composition of the disclosure;
[0042] detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject; and
[0043] determining a level of SV2 in the at least one portion of the subject.
[0044] In another aspect, the disclosure provides a method for detecting a disease or disorder involving synaptic disruptions and / or synaptic abnormalities in a subject. In certain embodiments, the method comprises:
[0045] administering to the subject at least one compound of the disclosure or the pharmaceutical composition of the disclosure;
[0046] detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject;
[0047] determining a level of SV2 in the at least one portion of the subject; and comparing the level of SV2 in the at least one portion of the subject to a SV2 level in a control subject who is not affected by the disease or disorder;
[0048] wherein the disease or disorder is detected in the subject if the SV2 level in the at least one portion of the subject’s body is lower than in the control subject.
[0049] BRIEF DESCRIPTION OF THE FIGURES
[0050] The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments of the present application.
[0051] FIGs. 1A-1D: FIGs. 1A-1B: concentration of18FSDM-18 in NHP’s plasma overtime under baseline and blocking conditions from 0 to 120 min after injection (FIG. 1A) and from 0 to 15 min after injection (FIG. 1B). FIG. 1C: parent fractions of18F-SDM-18 in plasma over time under baseline conditions. FIG. 1D: representative radio-high-performance liquid chromatographs of plasma content at 5, 15, 30, 60, 90, and 120 min after intravenous injection of18F-SDM-18 in NHP.
[0052] FIGs. 2A-2C: FIGs. 2A-2B: time-activity curves derived from single representative [18F]SDM-18 baseline scan (FIG. 2A) and blocking scan (FIG. 2B) with levetiracetam inAttorney Docket No. 047162-7570W01(02947)
[0053] NHP brain, displayed with ITC model fitted curves. FIG. 2C: summed SUV PET images of representative [18F]SDM-18 baseline and blocking scan, from 30 to 45 min after injection.
[0054] FIGs. 3A-3B: FIG. 3A: displacement study of [18F] SDM-18, with levetiracetam given at 90 min post-injection. FIG. 3B: summed SUV PET images of representative [18F]SDM-18 from 60 to 90 min and 150 to 180 min after injection.
[0055] FIG. 4: Lassen plot of [18F]SDM-18 in NHPs Brain.
[0056] FIGs. 5A-5B: Time stability analyses of outcome parameters of [18F]SDM-18 were calculated using ITC model on data from different scan times and divided by corresponding values measured using 120 min of PET data under baseline (FIG. 5A) and blocking (FIG. 5B) conditions.
[0057] FIGs. 6A-6C: FIGs. 6A-6B: time-activity curves derived from single representative [18F]SDM-18 baseline scan (FIG. 6A) and blocking scan (FIG. 6B) with levetiracetam in NHP spinal cord displayed with ITC model fitted curves. FIG. 6C: summed SUV PET images of representative [18F]SDM-18 baseline scan, from 30 to 45 min after injection.
[0058] FIG. 7: Lassen plot of [18F]SDM-18 in NHPs spinal cord.
[0059] FIG. 8: Graphs demonstrating binding of Padsevonil to SV2A, SV2B, and SV2C in HEK293 cells.
[0060] FIGs. 9A-9B: Graph depicting Kivalues (FIG. 9A) for certain exemplary compounds against SV2A and SV2C and ratios thereof (FIG. 9B)
[0061] FIGs. 10A-10O: Graphs depicting SV2A, SV2B, SV2C binding competition assay results for compounds SDM-19 (FIG. 10A), SDM-20 (FIG. 10B), SDM-21 (FIG. 10C), SDM-22 (FIG. 10D), SDM-23 (FIG. 10E), SDM-25 (FIG. 10F), SDM-26 (FIG. 10G), SDM-27 (FIG. 10H), SDM-28 (FIG. 10I), UCB-J (FIG. 10J), CZ-A (R) (CZ-B-1-1) (FIG. 10K), CZ-C ( ) (SDM-18) (FIG. 10L), SDM-8 (FIG. 10M). CZ-A (S) (CZ-B-1-2) (FIG. 10N), and CZ-C (S) (SDM-18 (S)) (FIG. 10O) against3H-Padsevonil in HEK293 cells.
[0062] FIG. 11: Overlay graph depicting SV2A binding competition assays for certain compounds of the disclosure and controls displacing3H-Padsevonil in HEK-293 cells.
[0063] FIG. 12: Graph depicting Kivalues for certain exemplary compounds against SV2A.
[0064] FIG. 13: Graph depicting competition assays using3H-UCB-J and human cortical grey matter homogenates.
[0065] FIG. 14: Graph depicting K, values for certain exemplary compounds against SV2A.
[0066] DETAILED DESCRIPTION OF THE INVENTION
[0067] Reference will now be made in detail to certain embodiments of the disclosed subjectAttorney Docket No. 047162-7570W01(02947)
[0068] matter, examples of which are illustrated in part in the accompanying drawings. While the disclosed subject matter will be described in conjunction with the enumerated claims, it will be understood that the exemplified subject matter is not intended to limit the claims to the disclosed subject matter.
[0069] Throughout this document, values expressed in a range format should be interpreted in a flexible manner to include not only the numerical values explicitly recited as the limits of the range, but also to include all the individual numerical values or sub-ranges encompassed within that range as if each numerical value and sub-range is explicitly recited. For example, a range of “about 0.1% to about 5%” or “about 0.1% to 5%” should be interpreted to include notjust about 0.1% to about 5%, but also the individual values (e.g., 1%, 2%, 3%, and 4%) and the sub-ranges (e.g., 0.1% to 0.5%, 1.1% to 2.2%, 3.3% to 4.4%) within the indicated range. The statement “about X to Y” has the same meaning as “about X to about Y,” unless indicated otherwise. Likewise, the statement “about X, Y, or about Z” has the same meaning as “about X, about Y, or about Z,” unless indicated otherwise.
[0070] In this document, the terms “a.” “an.” or “the” are used to include one or more than one unless the context clearly dictates otherwise. The term “or” is used to refer to a nonexclusive “or” unless otherwise indicated. The statement “at least one of A and B” or “at least one of A or B” has the same meaning as “A, B, or A and B.” In addition, it is to be understood that the phraseology or terminology employed herein, and not otherwise defined, is for the purpose of description only and not of limitation. Any use of section headings is intended to aid reading of the document and is not to be interpreted as limiting; information that is relevant to a section heading may occur within or outside of that particular section. All publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference.
[0071] In the methods described herein, the acts can be carried out in any order, except when a temporal or operational sequence is explicitly recited. Furthermore, specified acts can be carried out concurrently unless explicit claim language recites that they be carried out separately. For example, a claimed act of doing X and a claimed act of doing Y can be conducted simultaneously within a single operation, and the resulting process will fall within the literal scope of the claimed process.
[0072] Description
[0073] To overcome the challenges of functional imaging of the spinal cord using PET, advancements in high-resolution and high-sensitivity PET scanners, as well as the
[0074] Attorney Docket No. 047162-7570W01(02947)
[0075] development of novel radiotracers targeting specific biomarkers, are ongoing. One such target is the synaptic vesicle glycoprotein 2A (SV2A), which has gained attention as a biomarker for PET imaging in the brain, allowing for the assessment of synaptic density in various neurodegenerative and neuropsychiatric disorders. Since SV2A is predominantly expressed in the gray matter of the mammalian spinal cord, studies have utilized the SV2A-specific tracer, [nC]UCB-J, to assess synaptic density in both human and rat spinal cords. However, the Bmax of SV2A in the entire spinal cord is about 20 times lower than in the cerebral cortex, resulting in a relatively low binding potential (BPND) of -0.45, limiting its effectiveness for functional imaging of human spinal cord. In one aspect, the disclosure describes certain SV2A radioligands, including [18F]SDM-18, which were developed through structural modifications based on the pharmacophore of UCB-A and SDM-16. These new radioligands show improved brain kinetics and offers potential for better imaging. Thus, the disclosure describes the PET imaging evaluation of certain exemplary compounds (e.g., [18F]SDM-18) for quantify ing SV2A in both the brain and spinal cord of nonhuman primates (NHPs).
[0076] The disclosure demonstrates that [18F]SDM-18 had a higher BPNDcompared to other previously reported SV2A-specific radiotracers, and its VTremained stable over time in the rhesus monkey brain, indicating no substantial accumulation of radiometabolites.
[0077] Furthermore, [18F]SDM-18 uptake in the brain to measure receptor occupancy of SV2A was high at 83% with VND(9.4 mL / cm3) falling within the acceptable range, when LEV was used as the blocking agent. Despite its significance, effective PET tracers for detecting SV2A in the SC are lacking, primarily due to its small size and lower protein concentration. In 2022, a study was reported to study the feasibility of imaging SV2A in the SC with [nC]UCB-J. By utilizing simplified reference tissue model 2 (SRTM2) fit of the full SC ROI TAC acquired from Siemens mCT scanner, VTof the full SC was estimated to be 2.90 mL / cm3, using whole brain GM as reference region albeit low SV2A BPNDof 0.43. [nC]UCB-J uptake in the cervical region was measured to be higher than thoracic region, with DVR values of cSC ~1.3 times more than that of tSC. Unfortunately, [nC]UCB-J may not be an ideal PET tracer to study the pattern of SV2A heterogeneity within SC due to its low specific binding.
[0078] Quantitative accuracies in low thoracic regional uptake estimates due to low BPNDof [11C]UCB-J, were further confounded by its proximity to the liver, which was found to have significant tracer uptake.
[0079] On the contrary’, it was proposed that [18F]SDM-18, with its high BPND essential for accurate quantification, could be an ideal candidate to investigate the potential of imagingAttorney Docket No. 047162-7570W01(02947)
[0080] SV2A in characterizing regional SC pathophysiology using PET. The spinal cord occupancy of [18F]SDM-18. determined via Lassen Plot, was found to be 76%. Remarkably, the longitudinal distribution of SV2A across the rhesus monkey SC was investigated to study the pattern of heterogeneity in synaptic density. Similar to [nC]UCB-J, there was a general higher uptake in the cervical and lumbar regions than that of thoracic regions - the mean baseline VTof cSC, tSC and lSC was derived to be 38.4 mL / cm3(± 5.0%), 18.3 mL / cm3(± 3.5%) and 42.6 mL / cm3(± 8.1%) respectively. Notably, in the full SC [18F]SDM-18 BPND(5.66) was more than 10 times that of [11C]UCB-J (~0.45), rendering its usefulness as an ideal SV2A specific radiotracer to evaluate the changes in synaptic integrity across the full SC.
[0081] Thus, the disclosure indicates that PET imaging using [18F]SDM-18 is a viable approach in measuring and evaluating synaptic density changes through SV2A in rhesus monkey brain and spinal cord. The disclosure further demonstrates its potential in validating the specific binding and distribution of SV2A throughout the entire spinal cord, encompassing the cervical, thoracic and lumbar regions. It is hypothesized herein that [18F]SDM-18 can be translated and validated for clinical settings to study and monitor progression of patients with spinal cord injury and diseases such as ALS.
[0082] Definitions
[0083] The term “about’ ’ as used herein can allow for a degree of variability in a value or range, for example, within 10%, within 5%, or within 1 % of a stated value or of a stated limit of a range, and includes the exact stated value or range.
[0084] The term “alkenyl” as used herein refers to straight and branched chain and cyclic alkyl groups as defined herein, except that at least one double bond exists between two carbon atoms. Thus, alkenyl groups have from 2 to 40 carbon atoms, or 2 to about 20 carbon atoms, or 2 to 12 carbon atoms or, in some embodiments, from 2 to 8 carbon atoms.
[0085] Examples include, but are not limited to vinyl, -CH=C=CCH2, -CH=CH(CH3), -CH=C(CH3)2, -C(CH3)=CH2, -C(CH3)=CH(CH3), -C(CH2CH3)=CH2, cyclohexenyl, cyclopentenyl, cyclohexadienyl, butadienyl, pentadienyl, and hexadienyl among others.
[0086] The term “alkoxy” as used herein refers to an oxygen atom connected to an alkyl group, including a cycloalkyl group, as are defined herein. Examples of linear alkoxy groups include but are not limited to methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, and the like. Examples of branched alkoxy include but are not limited to isopropoxy, sec-butoxy, tert-butoxy, isopentyloxy, isohexyloxy, and the like. Examples of cyclic alkoxy include butAttorney Docket No. 047162-7570W01(02947)
[0087] are not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like. An alkoxy group can include about 1 to about 12, about 1 to about 20. or about 1 to about 40 carbon atoms bonded to the oxygen atom, and can further include double or triple bonds, and can also include heteroatoms. For example, an allyloxy group or a methoxyethoxy group is also an alkoxy group within the meaning herein, as is a methylenedioxy group in a context where two adjacent atoms of a structure are substituted therewith.
[0088] The term “alkyl’ ’ as used herein refers to straight chain and branched alkyl groups and cycloalkyl groups having from 1 to 40 carbon atoms, 1 to about 20 carbon atoms, 1 to 12 carbons or, in some embodiments, from 1 to 8 carbon atoms. Examples of straight chain alkyl groups include those with from 1 to 8 carbon atoms such as methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, n-heptyl, and n-octyl groups. Examples of branched alkyl groups include, but are not limited to, isopropyl, iso-butyl, sec-butyl, t-butyl, neopentyl, isopentyl, and 2,2-dimethylpropyl groups. As used herein, the term “alkyl” encompasses n-alkyl, isoalkyl, and anteisoalkyl groups as well as other branched chain forms of alkyl. Representative substituted alkyl groups can be substituted one or more times with any of the groups listed herein, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups.
[0089] The term “alkylene” or “alkylenyl” as used herein refers to a bivalent saturated aliphatic radical (e.g., -CH2-, -CH2CH2-, and -CH2CH2CH2-, inter alia). In certain embodiments, the term may be regarded as a moiety derived from an alkene by opening of the double bond or from an alkane by removal of two hydrogen atoms from the same (e.g. -CH2-) different (e.g., -CH2CH2-) carbon atoms.
[0090] The term “alkynyl” as used herein refers to straight and branched chain alkyd groups, except that at least one triple bond exists between two carbon atoms. Thus, alkynyl groups have from 2 to 40 carbon atoms, 2 to about 20 carbon atoms, or from 2 to 12 carbons or, in some embodiments, from 2 to 8 carbon atoms. Examples include, but are not limited to -C≡CH, -C≡C(CH3), -C≡C(CH2CH3), -CH2C≡CH, -CH2C≡C(CH3), and -CH2C≡C(CH2CH3) among others.
[0091] The term “amine” as used herein refers to primary, secondary, and tertiary amines having, e.g, the formula N(group)3wherein each group can independently be H or non-H, such as alkyl, ary l, and the like. Amines include but are not limited to R-NH2, for example, alky lamines, ary lamines, alkylarylamines; R2NH wherein each R is independently selected, such as dialkylamines, diarylamines, aralkylamines, heterocyclylamines and the like; and R3N wherein each R is independently selected, such as trialkylamines, dialkylarylamines,Attorney Docket No. 047162-7570W01(02947)
[0092] alkyldiarylamines, triarylamines, and the like. The term “amine” also includes ammonium ions as used herein.
[0093] The term “amino group” as used herein refers to a substituent of the form -NH2, -NHR, -NR2, or -NRC, wherein each R is independently selected, and protonated forms of each, except for -NR3+, which cannot be protonated. Accordingly, any compound substituted with an amino group can be viewed as an amine. An “amino group” within the meaning herein can be a primary, secondary, tertiary, or quaternary amino group. An “alkylamino” group includes a monoalkylamino, dialkylamino, and trialkylamino group.
[0094] The term “aralkyl” as used herein refers to alkyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an aryl group as defined herein. Representative aralkyl groups include benzyl and phenylethyl groups and fused (cycloalkylaryl)alkyl groups such as 4-ethyl-indanyl. Aralkenyl groups are alkenyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to an ary l group as defined herein.
[0095] The term "aryl" as used herein refers to cyclic aromatic hydrocarbon groups that do not contain heteroatoms in the ring. Thus aryl groups include, but are not limited to, phenyl, azulenyl, heptalenyl, biphenyl, indacenyl, fluorenyl, phenanthrenyl, triphenylenyl, pyrenyl, naphthacenyl, chrysenyl, biphenylenyl, anthracenyl, and naphthyl groups. In some embodiments, aryl groups contain about 6 to about 14 carbons in the ring portions of the groups. Aryl groups can be unsubstituted or substituted, as defined herein. Representative substituted aryl groups can be mono-substituted or substituted more than once, such as, but not limited to, a phenyl group substituted at any one or more of 2-, 3-, 4-, 5-, or 6-positions of the phenyl ring, or a naphthyl group substituted at any one or more of 2- to 8-positions thereof.
[0096] The term “cycloalkyl” as used herein refers to cyclic alkyl groups such as, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl groups. In some embodiments, the cycloalkyl group can have 3 to about 8-12 ring members, whereas in other embodiments the number of ring carbon atoms range from 3 to 4, 5, 6, or 7. Cycloalkyl groups further include polycyclic cycloalkyl groups such as, but not limited to, norbornyl, adamantyl, bornyl, camphenyl, isocamphenyl, and carenyl groups, and fused rings such as, but not limited to, decalinyl, and the like. Cycloalkyl groups also include rings that are substituted with straight or branched chain alkyl groups as defined herein. Representative substituted cycloalkyl groups can be mono-substituted or substituted more than once, such as, but not limited to, 2,2-, 2,3-, 2,4- 2,5- or 2,6-disubstituted cyclohexyl groups or mono-, di- orAttorney Docket No. 047162-7570W01(02947)
[0097] tri-substituted norbomyl or cycloheptyl groups, which can be substituted with, for example, amino, hydroxy, cyano, carboxy, nitro, thio, alkoxy, and halogen groups. The term “cycloalkenyl” alone or in combination denotes a cyclic alkenyl group.
[0098] The term “cycloalkylene” or “cycloalkylenyl” as used herein refers to a bivalent saturated cycloalkyl radical (e.g., A,
[0099]
[0100] inter alia). In certain embodiments, the term may be regarded as a product of removal of two hydrogen atoms from the corresponding cycloalkane (e.g, cyclobutyl) by removal of two hydrogen atoms from the same (e.g, different (e.g. U and
[0101]
[0102] carbon atoms.
[0103] A “disease” is a state of health of an animal wherein the animal cannot maintain homeostasis, and wherein if the disease is not ameliorated then the animal’s health continues to deteriorate.
[0104] In contrast, a “disorder” in an animal is a state of health in which the animal is able to maintain homeostasis, but in which the animal’s state of health is less favorable than it would be in the absence of the disorder. Left untreated, a disorder does not necessarily cause a further decrease in the animal’s state of health.
[0105] A disease or disorder is “ameliorated” if the severity of a symptom of the disease or disorder, the frequency with which such a symptom is experienced by a patient, or both, is reduced.
[0106] As used herein, the terms “effective amount,” “pharmaceutically effective amount” and “therapeutically effective amount” refer to a nontoxic but sufficient amount of an agent to provide the desired biological result. That result may be reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. An appropriate therapeutic amount in any individual case may be determined by one of ordinary skill in the art using routine experimentation.
[0107] The terms “halo,” “halogen,” or “halide” group, as used herein, by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom.
[0108] The term “haloalkyl” group, as used herein, includes mono-halo alkyl groups, polyhalo alkyl groups wherein all halo atoms can be the same or different, and per-halo alkyl groups, wherein all hydrogen atoms are replaced by halogen atoms, such as fluoro. Examples of haloalkyl include trifluoromethyl. 1,1 -di chloroethyl, 1.2-di chloroethyl, l,3-dibromo-3,3-difluoropropyl, perfluorobutyl, and the like.
[0109] Attorney Docket No. 047162-7570W01(02947)
[0110] The term “heteroaryl” as used herein refers to aromatic ring compounds containing 5 or more ring members, of which, one or more is a heteroatom such as, but not limited to. N, O, and S; for instance, heteroaryl rings can have 5 to about 8-12 ring members. A heteroaryl group is a variety of a heterocyclyl group that possesses an aromatic electronic structure. A heteroaryl group designated as a C2-heteroaryl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth.
[0111] Likewise a C4-heteroaryl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms sums up to equal the total number of ring atoms. Heteroaryl groups include, but are not limited to, groups such as pyrrolyl. pyrazolyl, triazolyl, tetrazolyk oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiophenyl, benzothiophenyl, benzofuranyl, indolyl. azaindolyl. indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Heteroaryl groups can be unsubstituted, or can be substituted with groups as is discussed herein. Representative substituted heteroaryl groups can be substituted one or more times with groups such as those listed herein.
[0112] Additional examples of aryl and heteroaryl groups include but are not limited to phenyl, biphenyl, indenyl, naphthyl (1-naphthyl, 2-naphthyl), N-hydroxytetrazolyl. N-hydroxytriazolyl, N-hydroxyimidazolyL anthracenyl (1-anthracenyl, 2-anthracenyl, 3-anthracenyl), thiophenyl (2 -thienyl, 3-thienyl), furyl (2-furyl, 3-furyl), indolyl, oxadiazolyl, isoxazolyl, quinazolinyl, fluorenyl, xanthenyl, isoindanyl, benzhydryl. acridinyl, thiazolyl, pyrrolyl (2-pyrrolyl), pyrazolyl (3-pyrazolyl), imidazolyl (1 -imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), triazolyl (1,2,3-triazol-l-yl, l,2,3-triazol-2-yl l,2,3-triazol-4-yl. l,2,4-triazol-3-yl), oxazolyl (2-oxazolyl, 4-oxazolyl, 5-oxazolyl), thiazolyl (2 -thiazolyl, 4-thiazolyl, 5-thiazolyl), pyridyl (2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (2-pyrimidinyl, 4-pyrimidinyl, 5 -pyrimidiny l, 6-pyrimidinyl), pyrazinyl, pyridazinyl (3- pyridazinyl, 4-pyridazinyl, 5 -pyridazinyl), quinolyl (2-quinolyl, 3-quinolyl, 4-quinolyl, 5-quinolyl, 6-quinolyL 7-quinolyL 8-quinolyl), isoquinolyl (1 -isoquinolyl, 3-isoquinolyl, 4-isoquinolyl, 5-isoquinolyl, 6-isoquinolyl, 7-isoquinolyl, 8-isoquinolyl), benzo[b]furanyl (2-benzo[b]furanyl, 3-benzo[b]furanyl, 4-benzo[b] furanyl, 5-benzo[b]furanyl, 6-benzo[b] furanyl, 7-benzo[b] furanyl), 2,3-dihydro-benzo[b]furanyl (2-(2,3-dihydro-benzo[b]furanyl), 3-(2,3-dihydro-benzo[b] furanyl), 4-(2,3-dihydro-benzo[b]furanyl), 5-(2.3-dihydro-benzo[b]furanyl), 6-(2,3-dihydro-benzo[b]furanyl), 7-(2,3-dihydro-benzo[b]furanyl), benzo[b]thiophenyl (2-
[0113] Attorney Docket No. 047162-7570W01(02947)
[0114] benzo[b]thiophenyl, 3-benzo[b]thiophenyl, 4-benzo[b]thiophenyl, 5-benzo[b]thiophenyl, 6-benzo[b]thiophenyl, 7-benzo[b]thiophenyl). 2,3-dihydro-benzo[b]thiophenyl, (2-(2,3-dihydro-benzo[b]thiophenyl), 3-(2,3-dihydro-benzo[b]thiophenyl), 4-(2,3-dihydro-benzo[b]thiophenyl), 5-(2,3-dihydro-benzo[b]thiophenyl), 6-(2,3-dihydro-benzo[b]thiophenyl), 7-(2,3-dihydro-benzo[b]thiophenyl), indolyl (1-indolyl, 2-indolyl,
[0115] 3-indolyl, 4-indolyl, 5-indolyl. 6-indolyl, 7-indolyl), indazole (1-indazolyl, 3-indazolyl,
[0116] 4-indazolyl, 5-indazolyl, 6-indazolyl, 7-indazolyl), benzimidazolyl (1 -benzimidazolyl, 2-benzimidazolyl, 4-benzimidazolyl, -benzimidazolyl, 6-benzimidazolyl, 7-benzimidazolyl, 8-benzimidazolyl), benzoxazolyl (1-benzoxazolyl, 2-benzoxazolyl), benzothiazolyl (1-benzothiazolyl, 2-benzothiazolyl, 4-benzothiazolyl, 5 -benzothiazolyl, 6-benzothiazolyl, 7-benzothiazolyl), carbazolyl ( 1 -carbazolyl. 2-carbazolyl. 3-carbazolyl. 4-carbazolyl), 5H-dibenz[b,f] azepine (5H-dibenz[b,f| azepin- 1-yl, 5H-dibenz[b,f]azepine-2-yl,
[0117] 5H-dibenz[b,f]azepine-3-yl, 5H-dibenz[b,f]azepine-4-yl, 5H-dibenz[b,f]azepine-5-yl),
[0118] 10,1 l-dihydro-5H-dibenz[b,f] azepine (10,1 l-dihydro-5H-dibenz[b,f]azepine-l-yl,
[0119] 10,1 l-dihydro-5H-dibenz[b,f]azepine-2-yl, 10,1 l-dihydro-5H-dibenz[b,f|azepine-3-yl.
[0120] 10,1 l-dihydro-5H-dibenz[b,f]azepine-4-yl, 10,1 l-dihydro-5H-dibenz|b,f|azepine-5-yl), and the like.
[0121] The term “heteroarylalkyl” as used herein refers to alkyl groups as defined herein in which a hydrogen or carbon bond of an alkyl group is replaced with a bond to a heteroaryl group as defined herein.
[0122] The term “heterocycloalkyl” as used herein refers to an aliphatic, partially unsaturated or fully saturated, 3- to 14-membered ring system, including single rings of 3 to 8 atoms and bi- and tricyclic ring systems where at least one of the carbon atoms of the ring is replaced with a heteroatom such as. but not limited to, nitrogen, oxygen, sulfur, or phosphorus. A heterocycloalkyl can include one to four heteroatoms independently selected from oxygen, nitrogen, and sulfur, wherein a nitrogen and sulfur heteroatom optionally can be oxidized and a nitrogen heteroatom can be optionally substituted. Representative heterocycloalkyl groups include, but are not limited, to the following exemplary groups: pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl. piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl. The term heterocycloalkyl group can also be a C2 heterocycloalkyl, C2-C3 heterocycloalky l, C2-C4 heterocycloalkyl, C2-C5 heterocycloalkyl, C2-C6 heterocycloalkyl, C2-C7 heterocycloalkyl, C2-C8 heterocycloalkyl, C2-C9 heterocycloalkyl. C2-C10 heterocycloalkyl. C2-C11 heterocycloalkyl, and the like, up to and including a C2-14s heterocycloalkyl. For example, aAttorney Docket No. 047162-7570W01(02947)
[0123] C2 heterocycloalkyl comprises a group which has two carbon atoms and at least one heteroatom, including, but not limited to, aziridinyl. diazetidinyl, oxiranyl, thiiranyl, and the like. Alternatively, for example, a C5 heterocycloalkyl comprises a group which has five carbon atoms and at least one heteroatom, including, but not limited to, piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, diazepanyl, and the like. It is understood that a heterocycloalkyl group may be bound either through a heteroatom in the ring, where chemically possible, or one of carbons comprising the heterocycloalkyl ring. The heterocycloalkyl group can be substituted or unsubstituted.
[0124] The term “heterocyclyl” as used herein refers to aromatic and non-aromatic ring compounds containing three or more ring members, of which one or more is a heteroatom such as, but not limited to. N, O. and S. Thus, a heterocyclyl can be a cycloheteroalkyl, or a heteroaryl, or if polycyclic, any combination thereof. In some embodiments, heterocyclyl groups include 3 to about 20 ring members, whereas other such groups have 3 to about 15 ring members. A heterocyclyl group designated as a C2-heterocyclyl can be a 5-ring with two carbon atoms and three heteroatoms, a 6-ring with two carbon atoms and four heteroatoms and so forth. Likewise a C4-heterocyclyl can be a 5-ring with one heteroatom, a 6-ring with two heteroatoms, and so forth. The number of carbon atoms plus the number of heteroatoms equals the total number of ring atoms. A heterocyclyl ring can also include one or more double bonds. A heteroaryl ring is an embodiment of a heterocyclyl group. The phrase '“heterocyclyl group’7includes fused ring species including those that include fused aromatic and non-aromatic groups. For example, a dioxolanyl ring and a benzdioxolanyl ring system (methylenedioxyphenyl ring system) are both heterocyclyl groups within the meaning herein. The phrase also includes polycyclic ring systems containing a heteroatom such as, but not limited to, quinuclidyl. Heterocyclyl groups can be unsubstituted, or can be substituted as discussed herein. Heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, pyridinyl, thiopheny l, benzothiophenyl, benzofuranyl, dihydrobenzofuranyl, indolyl, dihydroindolyl, azaindolyl. indazolyl, benzimidazolyl, azabenzimidazolyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, imidazopyridinyl, isoxazolopyridinyl, thianaphthalenyl, purinyl, xanthinyl, adeninyl, guaninyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, quinoxalinyl, and quinazolinyl groups. Representative substituted heterocyclyl groups can be mono-substituted or substituted more than once, such as, but not limited to, piperidinyl or quinolinyl groups, which are 2-, 3-, 4-. 5-, or 6-substituted, or disubstituted with groups such as those listed herein.
[0125] Attorney Docket No. 047162-7570W01(02947)
[0126] The term “hydrocarbon” or “hydrocarbyl” as used herein refers to a molecule or functional group that includes carbon and hydrogen atoms. The term can also refer to a molecule or functional group that normally includes both carbon and hydrogen atoms but wherein all the hydrogen atoms are substituted with other functional groups.
[0127] As used herein, the term “hydrocarbyl” refers to a functional group derived from a straight chain, branched, or cyclic hydrocarbon, and can be alkyl, alkenyl, alkynyl, aryl, cycloalkyl, acyl, or any combination thereof. Hydrocarbyl groups can be shown as (Ca-Cb)hydrocarbyl, wherein a and b are integers and mean having any of a to b number of carbon atoms. For example, (Ci-C4)hydrocarbyl means the hydrocarbyl group can be methyl (Ci), ethyl (C2), propyl (C3). or butyl (C4), and (Co-Cb)hydrocarbyl means in certain embodiments there is no hydrocarbyl group.
[0128] The term “independently selected from” as used herein refers to referenced groups being the same, different, or a mixture thereof, unless the context clearly indicates otherwise. Thus, under this definition, the phrase “X1, X2, and X3are independently selected from noble gases” would include the scenario where, for example, X1, X2, and X3are all the same, where X1, X2, and X3are all different, where X1and X2are the same but X3is different, and other analogous permutations.
[0129] The term “organic group” as used herein refers to any carbon-containing functional group. Examples can include an oxygen-containing group such as an alkoxy group, aryloxy group, aralkyloxy group, oxo(carbonyl) group; a carboxyl group including a carboxylic acid, carboxylate, and a carboxylate ester; a sulfur-containing group such as an alkyl and aryl sulfide group; and other heteroatom-containing groups. Non-limiting examples of organic groups include OR, OOR, OC(O)N(R)2, CN, CF3, OCF3, R, C(O), methylenedioxy, ethylenedioxy, N(R)2, SR, SOR. SO2R, SO2N(R)2, SO3R. C(O)R. C(O)C(O)R.
[0130] C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, C(O)N(R)2, OC(O)N(R)2, C(S)N(R)2, (CH2)O-2N(R)C(O)R, (CH2)O-2N(R)N(R)2, N(R)N(R)C(O)R, N(R)N(R)C(O)OR, N(R)N(R)CON(R)2, N(R)SO2R, N(R)SO2N(R)2, N(R)C(O)OR, N(R)C(O)R, N(R)C(S)R, N(R)C(O)N(R)2, N(R)C(S)N(R)2, N(COR)COR, N(OR)R, C(=NH)N(R)2, C(O)N(OR)R, C(=NOR)R. and substituted or unsubstituted (Ci-Cioo)hydrocarbyl, wherein R can be hydrogen (in examples that include other carbon atoms) or a carbon-based moiety, and wherein the carbon-based moiety can be substituted or unsubstituted.
[0131] The terms “patient,” “subject,” or “individual” are used interchangeably herein, and refer to any animal, or cells thereof whether in vitro or in situ, amenable to the methods described herein. In a non-limiting embodiment, the patient, subject or individual is a human.
[0132] Attorney Docket No. 047162-7570W01(02947)
[0133] As used herein, the term “pharmaceutically acceptable” refers to a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively non-toxic, z.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
[0134] As used herein, the language “pharmaceutically acceptable salt” refers to a salt of the administered compounds prepared from pharmaceutically acceptable non-toxic acids or bases, including inorganic acids or bases, organic acids or bases, solvates, hydrates, or clathrates thereof.
[0135] Suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid. Examples of inorganic acids include hydrochloric, hydrobromic, hydriodic, nitric, carbonic, sulfuric (including sulfate and hydrogen sulfate), and phosphoric acids (including hydrogen phosphate and dihydrogen phosphate). Appropriate organic acids may be selected from aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids, examples of which include formic, acetic, propionic, succinic, glycolic, gluconic, lactic, malic, tartaric, citric, ascorbic, glucuronic, maleic, malonic, saccharin, fumaric, pyruvic, aspartic, glutamic, benzoic, anthranilic, 4-hydroxybenzoic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, benzenesulfonic, pantothenic, trifluoromethanesulfonic, 2-hydroxyethanesulfonic, p-toluenesulfonic. sulfanilic, cyclohexylaminosulfonic, stearic, alginic, P-hy dr oxy butyric, salicylic, galactaric and galacturonic acid.
[0136] As used herein, the term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” means a pharmaceutically acceptable material, composition or carrier, such as a liquid or solid filler, stabilizer, dispersing agent, suspending agent, diluent, excipient, thickening agent, solvent or encapsulating material, involved in carrying or transporting a compound described herein within or to the patient such that it may perform its intended function. Typically, such compounds are carried or transported from one organ, or portion of the body, to another organ, or portion of the body. Each carrier must be “acceptable” in the sense of being compatible with the other ingredients of the formulation, including the compound(s) described herein, and not injurious to the patient. Some examples of materials that may serve as pharmaceutically acceptable carriers include: sugars, such as lactose, glucose and sucrose; starches, such as com starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppositoryAttorney Docket No. 047162-7570W01(02947)
[0137] waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, com oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; surface active agents; alginic acid; pyrogen-free water; isotonic saline; Ringer’s solution; ethyl alcohol; phosphate buffer solutions; and other non-toxic compatible substances employed in pharmaceutical formulations. As used herein, ‘'pharmaceutically acceptable earner” also includes any and all coatings, antibacterial and antifungal agents, and absorption delaying agents, and the like that are compatible with the activity of the compound(s) described herein, and are physiologically acceptable to the patient. Supplementary active compounds may also be incorporated into the compositions. The “pharmaceutically acceptable carrier” may further include a pharmaceutically acceptable salt of the compound(s) described herein. Other additional ingredients that may be included in the pharmaceutical compositions used with the methods or compounds described herein are known in the art and described, for example in Remington’s Pharmaceutical Sciences (Genaro, Ed., Mack Publishing Co., 1985. Easton, PA), which is incorporated herein by reference.
[0138] The term “phenylene” or “phenylenyl” as used herein refers to a bivalent phenyl radical (e g., 1,4-phenylene). In certain embodiments, the term may be regarded as a divalent radical formed by the removal of two hydrogen atoms from a benzene moiety.
[0139] The term “substantially” as used herein refers to a majority of, or mostly, as in at least about 50%, 60%, 70%, 80%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more, or 100%. The term “substantially free of’ as used herein can mean having none or having a trivial amount of, such that the amount of material present does not affect the material properties of the composition including the material, such that the composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less. The term “substantially free of’ can mean having a trivial amount of, such that a composition is about 0 wt% to about 5 wt% of the material, or about 0 wt% to about 1 wt%, or about 5 wt% or less, or less than, equal to, or greater than about 4.5 wt%, 4, 3.5, 3, 2.5, 2, 1.5, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.01, or about 0.001 wt% or less, or about 0 wt%.
[0140] The term “substituted” as used herein in conjunction with a molecule or an organic group as defined herein refers to the state in which one or more hydrogen atoms contained therein are replaced by one or more non-hydrogen atoms. The term “functional group” orAttorney Docket No. 047162-7570W01(02947)
[0141] “substituent’' as used herein refers to a group that can be or is substituted onto a molecule or onto an organic group. Examples of substituents or functional groups include, but are not limited to, a halogen (e.g, F, Cl, Br, and I); an oxygen atom in groups such as hydroxy groups, alkoxy groups, ary I oxy groups, aralkyloxy groups, oxo(carbonyl) groups, carboxyl groups including carboxylic acids, carboxylates, and carboxylate esters; a sulfur atom in groups such as thiol groups, alkyl and aryl sulfide groups, sulfoxide groups, sulfone groups, sulfonyl groups, and sulfonamide groups; a nitrogen atom in groups such as amines, hydroxyamines, nitriles, nitro groups, N-oxides, hydrazides, azides, and enamines; and other heteroatoms in various other groups. Non-limiting examples of substituents that can be bonded to a substituted carbon (or other) atom include F, Cl, Br, I, OR, 0C(0)N(R)2, CN, NO, NO2, ONO2, azido, CF3, OCF3. R, O (oxo), S (thiono). C(O), S(O), methylenedioxy, ethylenedioxy, N(R)2, SR, SOR, SO2R, SO2N(R)2, SO3R, C(O)R, C(O)C(O)R, C(O)CH2C(O)R, C(S)R, C(O)OR, OC(O)R, C(0)N(R)2, OC(O)N(R)2, C(S)N(R)2, (CH2)O-2N(R)C(0)R, (CH2)O-2N(R)N(R)2, N(R)N(R)C(O)R, N(R)N(R)C(O)OR, N(R)N(R)C0N(R)2, N(R)SO2R. N(R)SO2N(R)2, N(R)C(O)OR, N(R)C(O)R, N(R)C(S)R, N(R)C(0)N(R)2, N(R)C(S)N(R)2, N(COR)COR, N(OR)R, C(=NH)N(R)2, C(O)N(OR)R, and C(=NOR)R, wherein R can be hydrogen or a carbon-based moiety; for example, R can be hydrogen, (Ci-C100) hydrocarbyl, alkyl, acyl, cycloalkyl, aryl, aralky l, heterocyclyl, hetcroaryl. or heteroarylalkyl; or wherein two R groups bonded to a nitrogen atom or to adjacent nitrogen atoms can together with the nitrogen atom or atoms form a heterocyclyl.
[0142] The terms “treat,” “treating” and “treatment,” as used herein, means reducing the frequency or severity with which symptoms of a disease or condition are experienced by a subject by virtue of administering an agent or compound to the subject.
[0143] Compounds
[0144] In one aspect the disclosure provides a compound of Formula (I), or a salt, solvate, tautomer, or stereoisomer thereof, or any mixtures thereof:
[0145]
[0146] wherein:
[0147] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alky l, CN, NO2, and N3;
[0148] Attorney Docket No. 047162-7570W01(02947)
[0149] R2a, R2b, R2C, R2d, and R2eare each independently selected from the group consisting of H and optionally substituted Ci-Ce alkyl,
[0150] wherein one of R2band R2cand one of Rlaand Rlfcan combine with the carbon atoms to which they are bound to form an optionally substituted Cs-Cs cycloalkenyl;
[0151] L is -(optionally substituted C1-C3 alkylenyl)-;
[0152] R3is selected from the group consisting
[0153]
[0154]
[0155] R4a. R4b, R4C, and R4d, if present, are each independently selected from the group consisting of H, F, Cl, Br, I, CN. NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-Ce alkynyl, optionally substituted C3-C8 cycloalkyd, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio ar l, and optionally substituted C2-C10 heteroaryl,
[0156] wherein one of R4aand R4dand one of R2dand R2ecan combine with the carbon atoms to which they are bound to form an optionally substituted Cs-Cs heterocycloalkenyl;
[0157] wherein at least one of Rla. Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4d. if present, is18F or a moiety comprising18F, or
[0158] wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C, CRld, CRle, CR2a, C(R2b)(R2c), C(R2d)(R2e), CR4a, CR4b, CR4c, and CR4dcomprisesnC.
[0159] In certain embodiments, the compound is not (R)-l-((3-fluoropyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one. In certain embodiments, the compound is not (R)-l-((3-methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one. In certain embodiments, the compound is not (R)-4-(3,5-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not (R)-4-(3-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,5-difluorophenyl)-l-((2-methyl-lH-imidazol-l-yl)methyl)pyrrolidin-2-Attorney Docket No. 047162-7570W01(02947)
[0160] one. In certain embodiments, the compound is not (S)-4-(3,5-difluorophenyl)-l-((2-methyl-lH-imidazol-l-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 1-((3-methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,4-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,5-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(4-fluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,4-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one. In certain embodiments, the compound is not l-(pyridin-4-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one. In certain embodiments, the compound is not l-((3-fluoropyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3-fluorophenyl)- 1-(pyridin-4-ylmethyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(4-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not l-((4-methylpyridin-3-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,4-difluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,5-difluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(4-fluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3,5-difluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin- 2-one. In certain embodiments, the compound is not 4-(3,4-difluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one. In certain embodiments, the compound is not l-(pyridin-3-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrohdin-2-one. In certain embodiments, the compound is not l-((4-fluoropyridin-3-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3-fluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(3-fluorophenyl)-I-(pyridin-3-ylmethyl)pyrrolidin-2-one. In certain embodiments, the compound is not 4-(4-fluorophenyl)-I-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one.
[0161] In certain embodiments, L is -CH2-.
[0162] In certain embodiments, R2ais H. In certain embodiments, R21’ is H. In certain embodiments, R2cis H. In certain embodiments. R2dis H. In certain embodiments, R2eis H.
[0163] In certain embodiments, R2bcombines with Rlato form an optionally substituted C3-Attorney Docket No. 047162-7570W01(02947)
[0164] Cs cycloalkenyl. In certain embodiments, R2bcombines with Rleto form an optionally substituted C3-C8 cycloalkenyl. In certain embodiments, R2ccombines with Rlato form an optionally substituted C3-C8 cycloalkenyl. In certain embodiments, R2ccombines with Rleto form an optionally substituted C3-C8 cycloalkenyl.
[0165] In certain embodiments, R2dcombines with R4ato form an optionally substituted C3-Cs heterocycloalkyl. In certain embodiments, R2dcombines with R4dto form an optionally substituted C3-C8 heterocycloalkyl. In certain embodiments, R2ecombines with R4ato form an optionally substituted C3-C8 heterocycloalkyl. In certain embodiments, R2ecombines with R4dto form an optionally substituted C3-C8 heterocycloalk l.
[0166] In certain embodiments, the compound of formula (I) is a compound of Formula (la):
[0167]
[0168] wherein:
[0169] Rla. Rlc, and Rleare each independently selected from the group consisting of H. F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and N
[0170] R4a, R4b, and R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0171] wherein at least one of Rla, Rlc, Rle, R4a, R4b, and R4c, is18F or a moiety comprising18F, or
[0172] wherein at least one carbon atom selected from the group consisting of CRla, CRlc. CRle, CR4a, CR4h, and CR4ccomprises “C.
[0173] In certain embodiments, the compound of formula (I) is a compound of Formula (lb):
[0174]
[0175] wherein:
[0176] Attorney Docket No. 047162-7570W01(02947)
[0177] Rlaand Rlbare each independently selected from the group consisting of H, F, Cl, Br, I. optionally substituted Ci-Ce alkyl. CN, NO2, and Ns;
[0178] R4ais selected from the group consisting of H, F, CL Br, I, CN, NO2, N3, substituted Ci-Ce alkyl, optionally substituted C2-C6 alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally- substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0179] R4band R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C6-C10 aryl, and optionally substituted C2-C10 heteroaryl;
[0180] wherein at least one of Rlb, Rld, R4a, R4b, and R4cis18F or a moiety comprising18F, or wherein at least one carbon atom selected from the group consisting of CRlb, CRld, CR4a. CR4b, and CR4ccomprisesnC.
[0181] In certain embodiments, the compound of formula (I) is a compound of Formula (Ic):
[0182]
[0183] wherein:
[0184] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl. Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;
[0185] R4aand R4bare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C6-C10 aryl, and optionally substituted C2-C10 heteroaryl;
[0186] wherein at least one of Rla, Rlb, Rlc, Rld, Rle, R4a, and R4bis18F or a moiety comprising18F, or
[0187] wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C. CRld, CRle, CR4a, and CR4bcomprisesnC.
[0188] In certain embodiments, the compound of formula (I) is a compound of Formula (Id):
[0189] Attorney Docket No. 047162-7570W01(02947)
[0190]
[0191] wherein:
[0192] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, CL Br, I, optionally substituted Ci-Ce alky l, CN, NO2, and N3;
[0193] R4aand R4dare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, substituted Ci-Ce alkyl, optionally substituted C2-C6 alkyL optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-Ce alkynyl, optionally substituted C3-C8 cycloalkyd, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0194] R4aand R4bare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, optionally substituted Ci-Ce alkyd, optionally substituted Ci-Ce heteroalkyd, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alky nyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0195] wherein at least one of Rla, Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4dis18F or a moiety7comprising18F, or
[0196] wherein at least one carbon atom selected from the group consisting of CRla, CRlb. CR1C. CRld, CRle, CR4a, CR4b, CR4c. and CR4dcomprisesnC.
[0197] In certain embodiments, the compound of formula (I) is a compound of Formula (le):
[0198]
[0199] wherein:
[0200] Rla, Rlc, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyd, CN, NO2, and N3;
[0201] R4a. R4b, R4C, and R4dare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce
[0202] Attorney Docket No. 047162-7570W01(02947)
[0203] heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0204] wherein at least one of Rla, Rlc, Rle, R4a, R4h, R4c, and R4dis18F or a moiety comprising18F, or
[0205] wherein at least one carbon atom selected from the group consisting of CRla, CRlc, CR16. CR4a, CR4b, CR4C, and CR4dcomprisesnC.
[0206] In certain embodiments, the compound of formula (I) is a compound of Formula (If-
[0207]
[0208] wherein:
[0209] Rla. Rlb, Rlc, Rld, and Rlcare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;
[0210] wherein at least one of Rla, Rlb, Rlc, Rld, and Rleis18F or a moiety comprising18F, or wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CRlc. CRld, and CRlecomprisesnC.
[0211] In certain embodiments, the compound of formula (I) is a compound of Formula (If-2)
[0212]
[0213] wherein:
[0214] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting ofH, F, Cl. Br. I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;
[0215] wherein at least one of Rla. Rlb, Rlc, Rld, and Rleis18F or a moiety comprising18F. or wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CRlc, CRld, and CRlecomprisesnC.
[0216] In certain embodiments, the compound of formula (I) is a compound of Formula (Ig):
[0217] Attorney Docket No. 047162-7570W01(02947)
[0218]
[0219] wherein:
[0220] R1a, R1b, Rlc, R1d, and Rleare each independently selected from the group consisting of H. F, Cl. Br. I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;
[0221] R4a, R4b, and R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0222] wherein at least one of Rla, Rlb, Rlc, Rld, Rle, R4a, R4b, and R4cis18F or a moiety comprising18F, or
[0223] wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CRlc. CRld, CRle, CR4a, CR4b. and CR4ccomprises “C.
[0224] In certain embodiments, the compound of formula (I) is a compound of Formula (Th):
[0225]
[0226] wherein:
[0227] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;
[0228] R4a, R4b, R4C, and R4dare each independently selected from the group consisting of H, F, Cl, Br. I, CN, NO2, Ns, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Cs heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0229] wherein at least one of Rla. Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4dis18F or a moiety comprising18F, or
[0230] wherein at least one carbon atom selected from the group consisting of CRla, CRlb,Attorney Docket No. 047162-7570W01(02947)
[0231] CRlc, CRld, CRle, CR4a, CR4b, CR4c, and CR4dcomprisesnC.
[0232] In certain embodiments, Rlais H. In certain embodiments, Rlais F. In certain embodiments, Rlais18F. In certain embodiments, Rlbis H. In certain embodiments, Rlbis F. In certain embodiments, Rlbis18F. In certain embodiments, Rlcis H. In certain embodiments, Rlcis F. In certain embodiments, Rlcis18F. In certain embodiments, Rldis H. In certain embodiments, Rldis F. In certain embodiments, Rldis18F. In certain embodiments, Rleis H. In certain embodiments, Rleis F. In certain embodiments, Rleis18F. In certain embodiments, Rla, Rlc, and Rleare each independently F or18F, and Rlband Rldare each H. In certain embodiments, Rla, Rlc, and Rleare each H and Rlband Rldare each independently F or18F.
[0233] In certain embodiments,
[0234]
[0235] certain embodiments, R4ais H. In certain embodiments, R4ais Me. In certain embodiments, R4ais / B LI. In certain embodiments, R4ais
[0236] CN. In certain embodiments, R4ais NO2. In certain embodiments, R4ais CF3. In certain embodiments, R4ais Cl. In certain embodiments, R4ais Br. In certain embodiments, R4ais I.
[0237] L '°
[0238] In certain embodiments, R4ais CN. In certain embodiments, R4ais / N. In certain embodiments, R4aand R4bare H. In certain embodiments, R4aand R4bcombine with the carbon atoms to which they are bound to form optionally substituted phenyl.
[0239] In certain embodiments,
[0240]
[0241] certain embodiments, R4ais H. In certain embodiments, R4ais Me. In certain embodiments, R4ais -C=CH. In certain embodiments, R4ais -CH2OH. In certain embodiments, R4ais NO2. In certain embodiments, R4ais I. In certain embodiments, R4bis H. In certain embodiments, R4cis H. In certain embodiments, R4dis H.
[0242] In certain embodiments,
[0243]
[0244] certain embodiments, R4ais H. In certain embodiments, R4ais CF3. In certain embodiments, R4bis H.
[0245] Attorney Docket No. 047162-7570W01(02947)
[0246] N
[0247] In certain embodiments, R
[0248]
[0249] . In certain embodiments, R' is
[0250]
[0251] . In
[0252]
[0253] certain embodiments,
[0254]
[0255] certain embodiments, R3is ON. in certain
[0256]
[0257] embodiments, R3isNO2. In certain embodiments, R3isCF3. In certain
[0258]
[0259] embodiments, R3is Cl. In certain embodiments, R3is Br incertain
[0260]
[0261] embodiments, R3is I. In certain embodiments, R3is ON in certain
[0262] embodiments, R3is
[0263]
[0264] .,. in certain
[0265] embodiments, R3is
[0266]
[0267] . In certain embodiments, R3is
[0268]
[0269] . In certain
[0270] embodiments, R3is
[0271]
[0272] . In certain embodiments, R3is
[0273]
[0274] . In certain
[0275] O2N
[0276] embodiments, R3is
[0277]
[0278] . In certain embodiments, R3is
[0279]
[0280] . In certain
[0281] CF3
[0282] N
[0283] N z
[0284] embodiments, R3isN
[0285] In certain embodiments, the compound of Formula (I) is Formula (Ig):
[0286] Attorney Docket No. 047162-7570W01(02947)
[0287]
[0288] In certain embodiments, Rlais H. In certain embodiments, Rlais F. In certain embodiments, Rlais18F. In certain embodiments, R1bis H. In certain embodiments, Rlbis F. In certain embodiments, Rlbis18F. In certain embodiments. Rlcis H. In certain embodiments, Rlcis F. In certain embodiments, Rlcis18F. In certain embodiments, Rldis H. In certain embodiments, Rldis F. In certain embodiments, Rldis18F. In certain embodiments, Rleis H. In certain embodiments, Rleis F. In certain embodiments, Rleis18F. In certain embodiments, R4ais H. In certain embodiments, R4bis H. In certain embodiments, R4cis H.
[0289] In certain embodiments, the compound of Formula (I) is Formula (Ih):
[0290]
[0291] In certain embodiments, Rlais H. In certain embodiments, Rlais F. In certain embodiments, Rlais18F. In certain embodiments, Rlbis H. In certain embodiments, Rlbis F. In certain embodiments, Rlbis18F. In certain embodiments, Rlcis H. In certain embodiments, Rlcis F. In certain embodiments, Rlcis18F. In certain embodiments, Rldis H. In certain embodiments, Rldis F. In certain embodiments, R1dis18F. In certain embodiments, Rleis H. In certain embodiments, Rleis F. In certain embodiments, Rleis18F. In certain embodiments, R4ais H. In certain embodiments, R4bis H. In certain embodiments, R4cis H. In certain embodiments, R4dis H.
[0292] In certain embodiments, each occurrence of substituted alkyl, substituted cycloalkenyl, substituted hetercycloalkenyl, substituted alkylenyl, substituted heteroalkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, substituted aryl, and substituted heteroaryl is independently optionally substituted with at least one substituent selected from the group consisting of Ci-Ce alkyl, C3-Cs cycloalkyl, C2-C 12 heterocycloalkyl, Ci-Ce hydroxyalkyl, halogen, CN, NO2 OR1, N(R.T)(RTT). Ci-Ce haloalkoxy, C3-Cs halocycloalkoxy, aryl, heteroaryl, (Ci-Ce alkylenyl)C(=O)N(RI)(Rn), (Ci-Ce alkylenyl)C(=O)ORI, O(Ci-C3alkylenyl)C(=O)ORn, O(Ci-C3alkylenyl)C(=O)N(RI)(Rn),
[0293] Attorney Docket No. 047162-7570W01(02947)
[0294] =O)2RI, S(=O)2N(RI)(Rn),
[0295]
[0296] (=O)NRIRn, wherein R1and Rnare each independently selected from the group consisting of H, -C(=O)(Ci-Ce alkyl), Ci-Ce alkyl, Ci-Ce haloalkyl, Ci-Ce heteroalkyl, Cs-Cs cycloalkyl, C2-Ci2heterocycloalkyl, Ci-Ci2aralky l, aryl, and heteroaryl.
[0297] In certain embodiments, the compound is selected from the group consisting of: l-((2-(tert-butyl)-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrohdin-2-one; l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-benzo[d]imidazole-2-carbonitrile;
[0298] l-((lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one;
[0299] 4-(3,5-difluorophenyl)-l-((2-nitro-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0300] l-((2-chloro-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one; 4-(3,5-di fluorophenyl)-! -((2-(4-methyl-l, 2, 5-oxadiazol-3-yl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidin-2-one;
[0301] 4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidin-2-one;
[0302] 4-(3,5-difluorophenyl)-l-((3-(trifluoromethyl)-lH-l,2,4-triazol-l-yl)methyl)pyrrolidin-2-one;
[0303] l-((3-methylpyridin-4-yl)methyl)-4-(2,4,6-trifluorophenyl)pyrrolidin-2-one;
[0304] l-((2-bromo-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one; 4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0305] (R)-4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0306] (S)-4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one; l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;
[0307] (R)-l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;
[0308] (S)-l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;
[0309] 4-(3,5-difluoropheny 1)- 1 -((2-(trifluoromethy 1)- IH-imidazol- 1 -yl)methy l)pyrrolidin-2-one;
[0310] (R)-4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0311] (S)-4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0312] Attorney Docket No. 047162-7570W01(02947)
[0313] 6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-l,2,3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;
[0314] (3aR,9bS)-6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-l,2,3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;
[0315] (3aS,9bR)-6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-l,2,3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;
[0316] (9S,9aR)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;
[0317] (9R,9aR)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b] [2,6]naphthyridin-7(5H)-one;
[0318] (9S,9aS)-9-(3,5-difluorophenyl)-8.9.9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;
[0319] (9R,9aS)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;
[0320] (R)-4-(3,5-difluorophenyl)-l-((3-iodopyridin-4-yl)methyl)pyrrolidin-2-one;
[0321] (S)-4-(3,5-difluorophenyl)-l-((3-iodopyridin-4-yl)methyl)pyrrolidm-2-one;
[0322] (R)-4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0323] (S)-4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0324] (R)-4-(3,5-difluorophenyl)-l-((3-ethynylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0325] (S)-4-(3,5-difluorophenyl)-l-((3-ethynylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0326] 4-(3,5-difluorophenyl)-l -((3-(hydroxymethyl)pyridin-4-yl)methyl)pyrrolidin-2-one; and
[0327] 4-(3,5-difluorophenyl)-l-((3-nitropyridin-4-yl)methyl)pyrrolidin-2-one; wherein at least one F is18F or at least one C isnC.
[0328] In certain embodiments, the compound is (R)-4-(3-fluoro-5-(fluoro-18F)phenyl)-l-((2-(trifluoromethyl)- 1 H-imidazol- 1 -yl)methyl)pyrrolidin-2-one.
[0329] The compounds described herein can possess one or more stereocenters, and each stereocenter can exist independently in either the R) or (S) configuration. In certain embodiments, compounds described herein are present in optically active or racemic forms. It is to be understood that the compounds described herein encompass racemic, optically-active, regioisomeric and stereoisomeric forms, or combinations thereof that possess the therapeutically useful properties described herein. Preparation of optically active forms is achieved in any suitable manner, including by way of non-limiting example, by resolution of the racemic form with recrystallization techniques, synthesis from optically-active startingAttorney Docket No. 047162-7570W01(02947)
[0330] materials, chiral synthesis, or chromatographic separation using a chiral stationary phase. In certain embodiments, a mixture of one or more isomer is utilized as the therapeutic compound described herein. In other embodiments, compounds described herein contain one or more chiral centers. These compounds are prepared by any means, including stereoselective synthesis, enantioselective synthesis and / or separation of a mixture of enantiomers and / or diastereomers. Resolution of compounds and isomers thereof is achieved by any means including, by way of non-limiting example, chemical processes, enzymatic processes, fractional crystallization, distillation, and chromatography.
[0331] The methods and formulations described herein include the use of N-oxides (if appropriate), crystalline forms (also known as polymorphs), solvates, amorphous phases, and / or pharmaceutically acceptable salts of compounds having the structure of any compound(s) described herein, as well as metabolites and active metabolites of these compounds having the same ty pe of activity7. Solvates include water, ether (e.g, tetrahydrofuran, methyl tert-buty l ether) or alcohol (e.g., ethanol) solvates, acetates and the like. In certain embodiments, the compounds described herein exist in solvated forms with pharmaceutically acceptable solvents such as water, and ethanol. In other embodiments, the compounds described herein exist in unsolvated form.
[0332] In certain embodiments, the compound(s) described herein can exist as tautomers. All tautomers are included within the scope of the compounds presented herein.
[0333] In certain embodiments, compounds described herein are prepared as prodrugs. A “prodrug’’ refers to an agent that is converted into the parent drug in vivo. In certain embodiments, upon in vivo administration, a prodrug is chemically converted to the biologically, pharmaceutically or therapeutically active form of the compound. In other embodiments, a prodrug is enzymatically metabolized by one or more steps or processes to the biologically, pharmaceutically or therapeutically active form of the compound.
[0334] In certain embodiments, sites on, for example, the aromatic ring portion of compound(s) described herein are susceptible to various metabolic reactions. Incorporation of appropriate substituents on the aromatic ring structures may reduce, minimize or eliminate this metabolic pathway. In certain embodiments, the appropriate substituent to decrease or eliminate the susceptibility7of the aromatic ring to metabolic reactions is, by way' of example only, a deuterium, a halogen, or an alkyl group.
[0335] Compounds described herein also include isotopically-labeled compounds wherein one or more atoms is replaced by an atom having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
[0336] Attorney Docket No. 047162-7570W01(02947)
[0337] Examples of isotopes suitable for inclusion in the compounds described herein include and are not limited to2H.3H.11C,13C,14C,36C1.18F,123I,125I,13N,15N,15O,17O,180.32P, and35S. In certain embodiments, isotopically-labeled compounds are useful in drug and / or substrate tissue distribution studies. In other embodiments, substitution with heavier isotopes such as deuterium affords greater metabolic stability (for example, increased in vivo half-life or reduced dosage requirements). In yet other embodiments, substitution with positron emitting isotopes, such as11C,18F,15O, and13N, is useful in Positron Emission Topography (PET) studies for examining substrate receptor occupancy. Isotopically-labeled compounds are prepared by any suitable method or by processes using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.
[0338] In certain embodiments, the compounds described herein are labeled by other means, including, but not limited to, the use of chromophores or fluorescent moieties, bioluminescent labels, or chemiluminescent labels.
[0339] The compounds described herein, and other related compounds having different substituents are synthesized using techniques and materials described herein and as described, for example, in Fieser & Fieser’s Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd’s Chemistry of Carbon Compounds, Volumes 1-5 and Suppiementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons. 1991), Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), March, Advanced Organic Chemistry 4* Ed., (Wiley 1992); Carey & Sundberg, Advanced Organic Chemistry 4th Ed., Vols. A and B (Plenum 2000,2001), and Green & Wuts, Protective Groups in Organic Synthesis 3rd Ed., (Wiley 1999) (all of which are incorporated by reference for such disclosure). General methods for the preparation of compound as described herein are modified by the use of appropriate reagents and conditions, for the introduction of the various moieties found in the formula as provided herein.
[0340] Compounds described herein are synthesized using any suitable procedures starting from compounds that are available from commercial sources, or are prepared using procedures described herein.
[0341] In certain embodiments, reactive functional groups, such as hydroxyl, amino, imino, thio or carboxy groups, are protected in order to avoid their unwanted participation in reactions. Protecting groups are used to block some or all of the reactive moieties and prevent such groups from participating in chemical reactions until the protective group is removed. In other embodiments, each protective group is removable by a different means. Protective groups that are cleaved under totally disparate reaction conditions fulfill the requirement of
[0342] Attorney Docket No. 047162-7570W01(02947)
[0343] differential removal.
[0344] In certain embodiments, protective groups are removed by acid. base, reducing conditions (such as, for example, hydrogenolysis), and / or oxidative conditions. Groups such as trityl, dimethoxytrityl, acetal and t-butyldimethylsilyl are acid labile and are used to protect carboxy and hydroxy reactive moieties in the presence of amino groups protected with Cbz groups, which are removable by hydrogenolysis, and Fmoc groups, which are base labile. Carboxylic acid and hydroxy reactive moieties are blocked with base labile groups such as, but not limited to, methyl, ethyl, and acetyl, in the presence of amines that are blocked with acid labile groups, such as t-butyl carbamate, or with carbamates that are both acid and base stable but hydrolytically removable.
[0345] In certain embodiments, carboxylic acid and hydroxy reactive moieties are blocked with hydrolytically removable protective groups such as the benzyl group, while amine groups capable of hydrogen bonding with acids are blocked with base labile groups such as Fmoc. Carboxylic acid reactive moieties are protected by conversion to simple ester compounds as exemplified herein, which include conversion to alkyd esters, or are blocked with oxidatively-removable protective groups such as 2,4-dimethoxybenzyl, while coexisting amino groups are blocked with fluoride labile silyl carbamates.
[0346] Allyl blocking groups are useful in the presence of acid- and base- protecting groups since the former are stable and are subsequently removed by metal or pi-acid catalysts. For example, an allyl-blocked carboxylic acid is deprotected with a palladium-catalyzed reaction in the presence of acid labile t-butyl carbamate or base-labile acetate amine protecting groups. Yet another form of protecting group is a resin to which a compound or intermediate is attached. As long as the residue is attached to the resin, that functional group is blocked and does not react. Once released from the resin, the functional group is available to react.
[0347] Typically blocking / protecting groups may be selected from allyl, benzyl (Bn), benzyloxy carbonyl (Cbz), allyloxy carbonyl (Alloc), methyl, ethyl, t-butyl, t-butyldimethylsilyl (TBDMS), 2-(trimethylsilyl)ethoxy carbonyl (Teoc), / -butyloxycarbonyl (Boc), para-methoxybenzyl (PMB), triphenylmethyl (trityl), acetyl, and fluorenylmethoxycarbonyl (FMOC).
[0348] Other protecting groups, plus a detailed description of techniques applicable to the creation of protecting groups and their removal are described in Greene & Wuts, Protective Groups in Organic Synthesis, 3rd Ed., John Wiley & Sons, New' York, NY, 1999, and Kocienski, Protective Groups, Thieme Verlag, New York, NY, 1994. which are incorporated herein by reference for such disclosure.
[0349] Attomey Docket No. 047162-7570W01(02947)
[0350] Table 1. Exemplary compounds of the disclosure
[0351]
[0352] Attorney Docket No. 047162-7570W01(02947)
[0353]
[0354] Attomey Docket No. 047162-7570W01(02947)
[0355]
[0356] Attomey Docket No. 047162-7570W01(02947)
[0357]
[0358] Attorney Docket No. 047162-7570W01(02947)
[0359]
[0360] In another aspect, the disclosure provides a pharmaceutical composition comprising the compound of the disclosure and at least one pharmaceutically acceptable earner.
[0361] Methods
[0362] In one aspect, the disclosure provides a method for imaging or detecting a Synaptic Vesicle Protein 2 (SV2) in a subject. In certain embodiments, the method comprises administering to the subject at least one compound of the disclosure or a pharmaceutical composition thereof. In certain embodiments, the method comprises detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject.
[0363] In one aspect, the disclosure provides a method for quantifying a Synaptic Vesicle Protein 2 (SV2) in a subject. In certain embodiments, the method comprises administering to the subject at least one compound of the disclosure or a pharmaceutical composition thereof. In certain embodiments, the method comprises detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject. In certain embodiments, the method comprises determining a level of SV2 in the at least one portion of the subject.
[0364] In one aspect, the disclosure provides a method for detecting a disease or disorder involving synaptic disruptions and / or synaptic abnormalities in a subject. In certain embodiments, the method comprises administering to the subject at least one compound of the disclosure or a pharmaceutical composition thereof. In certain embodiments, the method comprises detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject. In certain embodiments, the method comprises determining aAttorney Docket No. 047162-7570W01(02947)
[0365] level of SV2 in the at least one portion of the subject. In certain embodiments, the method comprises comparing the level of SV2 in the at least one portion of the subject to a SV2 level in a control subject who is not affected by the disease or disorder. In certain embodiments, the method comprises the disease or disorder is detected in the subject if the SV2 level in the at least one portion of the subject’s body is lower than in the control subject.
[0366] In certain embodiments, the portion of the subject comprises the entire nervous system of the subject. In certain embodiments, the portion of the subject comprises the brain of the subject. In certain embodiments, the portion of the subject comprises the spinal cord of the subject.
[0367] In certain embodiments, the portion of the brain comprises the amygdala. In certain embodiments, the portion of the brain comprises the brainstem. In certain embodiments, the portion of the brain comprises the caudate. In certain embodiments, the portion of the brain comprises the centrum semiovale. In certain embodiments, the portion of the brain comprises the cerebellum. In certain embodiments, the portion of the brain comprises the cingulate cortex. In certain embodiments, the portion of the brain comprises the frontal cortex. In certain embodiments, the portion of the brain comprises the globus pallidus. In certain embodiments, the portion of the brain comprises the hippocampus. In certain embodiments, the portion of the brain comprises the insula. In certain embodiments, the portion of the brain comprises the nucleus accumbens. In certain embodiments, the portion of the brain comprises the occipital cortex. In certain embodiments, the portion of the brain comprises the pons. In certain embodiments, the portion of the brain comprises the putamen. In certain embodiments, the portion of the brain comprises the temporal cortex. In certain embodiments, the portion of the brain comprises the thalamus.
[0368] In certain embodiments, the portion of the spinal cord comprises cervical region (e.g, C1-C7). In certain embodiments, the portion of the spinal cord comprises the thoracic region (e.g., T1-T12). In certain embodiments, the portion of the spinal cord comprises the lumbar region (e.g., L1-L5).
[0369] In certain embodiments, the quantifying permits measurement of synaptic density’.
[0370] In certain embodiments, the SV2 is SV2A. In certain embodiments, the SV2 is SV2B. In certain embodiments, the SV2 is and SV2C.
[0371] In certain embodiments, SV2A is selectively detected over SV2B. In certain embodiments, SV2A is selectively detected over SV2C. In certain embodiments, SV2B is selectively detected over SV2A. In certain embodiments, SV2B is selectively detected over SV2C. In certain embodiments, SV2C is selectively detected over SV2A. In certain
[0372] Attorney Docket No. 047162-7570W01(02947)
[0373] embodiments, SV2C is selectively detected over SV2B.
[0374] In certain embodiments, the disease or disorder is selected from the group consisting of a neurodegenerative disease or disorder, multiple sclerosis (MS), autism, epilepsy, stroke, traumatic brain injury (TBI), psychiatric disorder, and diabetes.
[0375] In certain embodiments, the neurodegenerative disease or disorder is selected from the group consisting of Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia, Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, dementia with Lewy bodies, and Creutzfeldt-Jakob disease (CJD).
[0376] Administration / Dosage / Formulations
[0377] The regimen of administration may affect what constitutes an effective amount. The therapeutic formulations may be administered to the subject either prior to or after the onset of the disease or disorder. Further, several divided dosages, as well as staggered dosages may be administered daily or sequentially, or the dose may be continuously infused, or may be a bolus injection. Further, the dosages of the therapeutic formulations may be proportionally increased or decreased as indicated by the exigencies of the therapeutic or prophylactic situation.
[0378] Administration of the compositions described herein to a patient, preferably a mammal, more preferably a human, may be carried out using known procedures, at dosages and for periods of time effective to treat the disease or disorder in the patient. An effective amount of the therapeutic compound necessary to achieve a therapeutic effect may vary according to factors such as the state of the disease or disorder in the patient; the age, sex, and weight of the patient; and the ability of the therapeutic compound to treat the disease or disorder in the patient. Dosage regimens may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A nonlimiting example of an effective dose range for a therapeutic compound described herein is from about 1 and 5,000 mg / kg of body weight / per day. One of ordinary skill in the art would be able to study the relevant factors and make the determination regarding the effective amount of the therapeutic compound without undue experimentation.
[0379] Actual dosage levels of the active ingredients in the pharmaceutical compositions described herein may be varied so as to obtain an amount of the active ingredient that is effective to achieve the desired therapeutic response for a particular patient, composition, andAttorney Docket No. 047162-7570W01(02947)
[0380] mode of administration, without being toxic to the patient.
[0381] In particular, the selected dosage level depends upon a variety of factors including the activity of the particular compound employed, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds or materials used in combination with the compound, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well, known in the medical arts.
[0382] A medical doctor, e.g., physician or veterinarian, having ordinary skill in the art may readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of the compounds described herein employed in the pharmaceutical composition at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
[0383] In particular embodiments, it is especially advantageous to formulate the compound in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the patients to be treated; each unit containing a predetermined quantity of therapeutic compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical vehicle. The dosage unit forms of the compound(s) described herein are dictated by and directly dependent on (a) the unique characteristics of the therapeutic compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding / formulating such a therapeutic compound.
[0384] In certain embodiments, the compositions described herein are formulated using one or more pharmaceutically acceptable excipients or carriers. In certain embodiments, the pharmaceutical compositions described herein comprise a therapeutically effective amount of a compound described herein and a pharmaceutically acceptable carrier.
[0385] The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity may be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms may be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it is preferable to include isotonic agents, for example, sugars, sodium chloride, orAttorney Docket No. 047162-7570W01(02947)
[0386] poly alcohols such as mannitol and sorbitol, in the composition. Prolonged absorption of the injectable compositions may be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate or gelatin.
[0387] In certain embodiments, the compositions described herein are administered to the patient in dosages that range from one to five times per day or more. In other embodiments, the compositions described herein are administered to the patient in range of dosages that include, but are not limited to, once every day, every two, days, every three days to once a week, and once every two weeks. It is readily apparent to one skilled in the art that the frequency of administration of the various combination compositions described herein varies from individual to individual depending on many factors including, but not limited to, age, disease or disorder to be treated, gender, overall health, and other factors. Thus, administration of the compounds and compositions described herein should not be construed to be limited to any particular dosage regime and the precise dosage and composition to be administered to any patient is determined by the attending physician taking all other factors about the patient into account.
[0388] The compound(s) described herein for administration may be in the range of from about 1 pg to about 10,000 mg, about 20 pg to about 9,500 mg, about 40 pg to about 9,000 mg, about 75 pg to about 8,500 mg, about 150 pg to about 7,500 mg, about 200 pg to about 7,000 mg, about 350 pg to about 6,000 mg, about 500 pg to about 5,000 mg, about 750 pg to about 4,000 mg, about 1 mg to about 3,000 mg, about 10 mg to about 2,500 mg, about 20 mg to about 2,000 mg, about 25 mg to about 1,500 mg, about 30 mg to about 1,000 mg, about 40 mg to about 900 mg, about 50 mg to about 800 mg, about 60 mg to about 750 mg, about 70 mg to about 600 mg, about 80 mg to about 500 mg, and any and all whole or partial increments therebetween.
[0389] In some embodiments, the dose of a compound described herein is from about 1 mg and about 2,500 mg. In some embodiments, a dose of a compound described herein used in compositions described herein is less than about 10,000 mg, or less than about 8,000 mg, or less than about 6,000 mg, or less than about 5.000 mg, or less than about 3,000 mg, or less than about 2,000 mg, or less than about 1,000 mg, or less than about 500 mg, or less than about 200 mg, or less than about 50 mg. Similarly, in some embodiments, a dose of a second compound as described herein is less than about 1,000 mg, or less than about 800 mg, or less than about 600 mg, or less than about 500 mg, or less than about 400 mg, or less than about 300 mg, or less than about 200 mg, or less than about 100 mg, or less than about 50 mg, or less than about 40 mg, or less than about 30 mg, or less than about 25 mg, or less than aboutAttorney Docket No. 047162-7570W01(02947)
[0390] 20 mg, or less than about 15 mg, or less than about 10 mg, or less than about 5 mg, or less than about 2 mg. or less than about 1 mg, or less than about 0.5 mg, and any and all whole or partial increments thereof.
[0391] In certain embodiments, a composition as described herein is a packaged pharmaceutical composition comprising a container holding a therapeutically effective amount of a compound described herein, alone or in combination with a second pharmaceutical agent; and instructions for using the compound to treat, or reduce one or more symptoms of a disease or disorder in a patient.
[0392] Formulations may be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art. The pharmaceutical preparations may be sterilized and if desired mixed with auxiliary’ agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and / or aromatic substances and the like. They may also be combined where desired with other active agents, e.g., other analgesic agents.
[0393] Routes of administration of any of the compositions described herein include oral, nasal, rectal, intravaginal, parenteral, buccal, sublingual or topical. The compounds for use in the compositions described herein can be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g.. sublingual, lingual, (trans)buccal, (trans)urethral, vaginal (e.g, trans- and perivaginally), (intra)nasal and (trans)rectal), intravesical, intrapulmonary, intraduodenal, intragastrical, intrathecal, subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, intrabronchial, inhalation, and topical administration.
[0394] Suitable compositions and dosage forms include, for example, tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays for nasal or oral administration, dry’ powder or aerosolized formulations for inhalation, compositions and formulations for intravesical administration and the like. It should be understood that the formulations and compositions described herein are not limited to the particular formulations and compositions that are described herein.
[0395] Oral Administration
[0396] For oral application, particularly suitable are tablets, dragees, liquids, drops.
[0397] Attorney Docket No. 047162-7570W01(02947)
[0398] suppositories, or capsules, caplets and gelcaps. The compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients that are suitable for the manufacture of tablets. Such excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate. The tablets may be uncoated or they may be coated by known techniques for elegance or to delay the release of the active ingredients. Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed wi th an inert diluent.
[0399] For oral administration, the compound(s) described herein can be in the form of tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g, polyvinylpyrrolidone, hydroxypropylcellulose or hydroxypropyl methylcellulose); fillers (e.g, cornstarch, lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g, magnesium stearate, talc, or silica); disintegrates (e.g, sodium starch glycollate); or wetting agents (e.g, sodium lauryl sulphate). If desired, the tablets may be coated using suitable methods and coating materials such as OPADRY™ film coating systems available from Colorcon, West Point, Pa. (e.g., OPADRY™ OY Type, OYC Type, Organic Enteric OY -P Type, Aqueous Enteric OY -A Type, OY -PM Type and OPADRY™ White, 32K18400). Liquid preparation for oral administration may be in the form of solutions, syrups or suspensions. The liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g. methyl or propyl p-hydroxy benzoates or sorbic acid).
[0400] Parenteral Administration
[0401] For parenteral administration, the compounds as described herein may be formulated for injection or infusion, for example, intravenous, intramuscular or subcutaneous injection or infusion, or for administration in a bolus dose and / or continuous infusion. Suspensions, solutions or emulsions in an oily or aqueous vehicle, optionally containing other formulatory agents such as suspending, stabilizing and / or dispersing agents may be used.
[0402] Sterile injectable forms of the compositions described herein may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxicAttorney Docket No. 047162-7570W01(02947)
[0403] parenterally-acceptable diluent or solvent, for example as a solution in 1, 3-butanediol.
[0404] Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. Sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or similar alcohol.
[0405] Additional Administration Forms
[0406] Additional dosage forms suitable for use with the compound(s) and compositions described herein include dosage forms as described in U. S. Patents Nos. 6,340,475;
[0407] 6,488,962; 6,451,808; 5,972,389; 5,582,837; and 5,007,790. Additional dosage forms suitable for use with the compound(s) and compositions described herein also include dosage forms as described in U. S. Patent Applications Nos. 20030147952; 20030104062; 20030104053; 20030044466; 20030039688; and 20020051820. Additional dosage forms suitable for use with the compound(s) and compositions described herein also include dosage forms as described in PCT Applications Nos. WO 03 / 35041; WO 03 / 35040; WO 03 / 35029; WO 03 / 35177; WO 03 / 35039; WO 02 / 96404; WO 02 / 32416; WO 01 / 97783; WO 01 / 56544; WO 01 / 32217; WO 98 / 55107; WO 98 / 11879; WO 97 / 47285; WO 93 / 18755; and WO 90 / 11757.
[0408] Controlled Release Formulations and Drug Delivery Systems
[0409] In certain embodiments, the formulations described herein can be, but are not limited to, short-term, rapid-offset, as well as controlled, for example, sustained release, delayed release and pulsatile release formulations.
[0410] The term sustained release is used in its conventional sense to refer to a drug formulation that provides for gradual release of a drug over an extended period of time, and that may, although not necessarily, result in substantially constant blood levels of a drug over an extended time period. The period of time may be as long as a month or more and should be a release which is longer that the same amount of agent administered in bolus form.
[0411] For sustained release, the compounds may be formulated with a suitable polymer or hydrophobic material which provides sustained release properties to the compounds. As such, the compounds for use with the method(s) described herein may be administered in the form of microparticles, for example, by injection or in the form of wafers or discs by implantation.
[0412] Attorney Docket No. 047162-7570W01(02947)
[0413] In some cases, the dosage forms to be used can be provided as slow or controlled-release of one or more active ingredients therein using, for example, hydropropylmethyl cellulose, other polymer matrices, gels, permeable membranes, osmotic systems, multilayer coatings, microparticles, liposomes, or microspheres or a combination thereof to provide the desired release profile in varying proportions. Suitable controlled-release formulations known to those of ordinary’ skill in the art, including those described herein, can be readily selected for use with the pharmaceutical compositions described herein. Thus, single unit dosage forms suitable for oral administration, such as tablets, capsules, gelcaps, and caplets that are adapted for controlled-release are encompassed by the compositions and dosage forms described herein.
[0414] Most controlled-release pharmaceutical products have a common goal of improving drug therapy over that achieved by their non-controlled counterparts. Ideally, the use of an optimally designed controlled-release preparation in medical treatment is characterized by a minimum of drug substance being employed to cure or control the condition in a minimum amount of time. Advantages of controlled-release formulations include extended activity of the drug, reduced dosage frequency, and increased patient compliance. In addition, controlled-release formulations can be used to affect the time of onset of action or other characteristics, such as blood level of the drug, and thus can affect the occurrence of side effects.
[0415] Most controlled-release formulations are designed to initially release an amount of drug that promptly produces the desired therapeutic effect, and gradually and continually release of other amounts of drug to maintain this level of therapeutic effect over an extended period of time. In order to maintain this constant level of drug in the body, the drug must be released from the dosage form at a rate that will replace the amount of drug being metabolized and excreted from the body.
[0416] Controlled-release of an active ingredient can be stimulated by various inducers, for example pH, temperature, enzymes, water, or other physiological conditions or compounds. The term “controlled-release component” is defined herein as a compound or compounds, including, but not limited to, polymers, polymer matrices, gels, permeable membranes, liposomes, or microspheres or a combination thereof that facilitates the controlled-release of the active ingredient. In some embodiments, the compound(s) described herein are administered to a patient, alone or in combination with another pharmaceutical agent, using a sustained release formulation. In some embodiments, the compound(s) described herein are administered to a patient, alone or in combination with another pharmaceutical agent, using aAttorney Docket No. 047162-7570W01(02947)
[0417] sustained release formulation.
[0418] The term delayed release is used herein in its conventional sense to refer to a drug formulation that provides for an initial release of the drug after some delay following drug administration and that may, although not necessarily, includes a delay of from about 10 minutes up to about 12 hours.
[0419] The term pulsatile release is used herein in its conventional sense to refer to a drug formulation that provides release of the drug in such a way as to produce pulsed plasma profiles of the drug after drug administration.
[0420] The term immediate release is used in its conventional sense to refer to a drug formulation that provides for release of the drug immediately after drug administration.
[0421] As used herein, short-term refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes and any or all whole or partial increments thereof after drug administration after drug administration.
[0422] As used herein, rapid-offset refers to any period of time up to and including about 8 hours, about 7 hours, about 6 hours, about 5 hours, about 4 hours, about 3 hours, about 2 hours, about 1 hour, about 40 minutes, about 20 minutes, or about 10 minutes, and any and all whole or partial increments thereof after drug administration.
[0423] Dosing
[0424] The therapeutically effective amount or dose of a compound described herein depends on the age, sex and weight of the patient, the current medical condition of the patient and the progression of the disease or disorder in the patient being treated. The skilled artisan is able to determine appropriate dosages depending on these and other factors.
[0425] A suitable dose of a compound described herein can be in the range of from about 0.01 mg to about 5,000 mg per day, such as from about 0.1 mg to about 1,000 mg, for example, from about 1 mg to about 500 mg, such as about 5 mg to about 250 mg per day. The dose may be administered in a single dosage or in multiple dosages, for example from 1 to 4 or more times per day. When multiple dosages are used, the amount of each dosage may be the same or different. For example, a dose of 1 mg per day may be administered as two 0.5 mg doses, with about a 12-hour interval between doses.
[0426] It is understood that the amount of compound dosed per day may be administered, in non-limiting examples, every day. every other day, every 2 days, every 3 days, every 4 days, or every 5 days. For example, with every other day administration, a 5 mg per day dose mayAttorney Docket No. 047162-7570W01(02947)
[0427] be initiated on Monday with a first subsequent 5 mg per day dose administered on Wednesday, a second subsequent 5 mg per day dose administered on Friday, and so on.
[0428] In the case wherein the patient’s status does improve, upon the doctor’s discretion the administration of the compound(s) described herein is optionally given continuously; alternatively, the dose of drug being administered is temporarily reduced or temporarily suspended for a certain length of time (z.e., a ‘"drug holiday”). The length of the drug holiday optionally varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during a drug holiday includes from 10%-100%, including, by way of example only, 10%, 15%, 20%. 25%. 30%. 35%. 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
[0429] Once improvement of the patient’s conditions has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, is reduced to a level at which the improved disease is retained. In certain embodiments, patients require intermittent treatment on a long-term basis upon any recurrence of symptoms and / or infection.
[0430] The compounds described herein can be formulated in unit dosage form. The term “unit dosage form” refers to physically discrete units suitable as unitary dosage for patients undergoing treatment, with each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, optionally in association with a suitable pharmaceutical carrier. The unit dosage form may be for a single daily dose or one of multiple daily doses (e g., about 1 to 4 or more times per day). When multiple daily doses are used, the unit dosage form may be the same or different for each dose.
[0431] Toxicity and therapeutic efficacy of such therapeutic regimens are optionally determined in cell cultures or experimental animals, including, but not limited to, the determination of the LDso (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between the toxic and therapeutic effects is the therapeutic index, which is expressed as the ratio between LDso and EDso. The data obtained from cell culture assays and animal studies are optionally used in formulating a range of dosage for use in human. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity. The dosage optionally varies within this range depending upon the dosage form employed and the route of administration utilized.
[0432] Attorney Docket No. 047162-7570W01(02947)
[0433] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures, embodiments, claims, and examples described herein. Such equivalents are considered to be within the scope of this disclosure and covered by the claims appended hereto. For example, it should be understood, that modifications in reaction conditions, including but not limited to reaction times, reaction size / volume, and experimental reagents, such as solvents, catalysts, pressures, atmospheric conditions, e.g., nitrogen atmosphere, and reducing / oxidizing agents, with art-recognized alternatives and using no more than routine experimentation, are within the scope of the present application.
[0434] It is to be understood that wherever values and ranges are provided herein, all values and ranges encompassed by these values and ranges, are meant to be encompassed within the scope of the present disclosure. Moreover, all values that fall within these ranges, as well as the upper or lower limits of a range of values, are also contemplated by the present application.
[0435] The following examples further illustrate aspects of the present disclosure. However, they are in no way a limitation of the teachings or disclosure of the present disclosure as set forth herein.
[0436] EXAMPLES
[0437] Various embodiments of the present application can be better understood by reference to the following Examples which are offered by way of illustration. The scope of the present application is not limited to the Examples given herein.
[0438] Materials and Methods
[0439] PET Imaging Experiments in Rhesus Monkeys
[0440] Injection Parameters
[0441] A total of 3 PET scans were performed in one monkey. Injected activity was 17.7 ± 0.8 MBq, with injected mass of 0.45 ± 0.017 pg.
[0442] Plasma analysis
[0443] [18F]SDM-18 radioactivity concentration in the plasma increased rapidly and a sharp decline distribution phase was observed within 5 min after administration, followed by a slow clearance phase. The plasma free fraction ( / P) of [18F]SDM-18 was determined to be high at 39 ± 4% (n = 3). The mean LogP value of [18F]SDM-18 was measured to be 2.37, which fallsAttorney Docket No. 047162-7570W01(02947)
[0444] within the optimal range for radiotracers to be brain penetrant. Parent fractions of [18F]SDM-18 was observed to decrease to about 20% within 15 min. demonstrating that metabolism rate was considerably high in this rhesus monkey. FIGs. 1A-1D displayed the representative radio chromatograms from plasma samples obtained at 5, 15, 30, 60, 90 and 120 min after injection of [18F]SDM-18 in rhesus monkey. The predominant radiometabolite with a retention time of ~ 0.67 min was eluting earlier than the parent fraction, indicating its higher hydrophilicity that might limit its ability to be BBB penetrant.
[0445] Competitive Binding Assay (SV2A, / SV2B / SV2C)
[0446] For experiments described in Example 3, FIG. 8, FIGs. 9A-9B, FIGs. 10A-10I, Tables 6A-6C. and Table 7. Prepared 10 mM DMSO stocks of competition compounds. Diluted competitor compound stocks 1: 10 in PBS then completed serial dilution to give row of 12 half-log dilutions of each compound descending from 100 pM. Added 20 pL of the compound to each row to 96-well plate done in quadruplicates. Diluted3H-Padsevonil tracer to 22.5 nM in PBS (final concentration 9 nM). Added 80 pL tracer to each well of all reaction plates. Thawed mock-infected, SV2A, SV2B, and SV2C expressing HEK cells, (2.5E7 cells / mL) and diluted to 4E6 cells / mL in PBS (final concentration 2E6 cells / well). Added 100 pL to each well of all reaction plates. Sealed plates and incubated at room temperature at 250 rpm for 90 minutes. Filtered onto Millipore GFC PEI plates and washed each with ~240 mL cold PBS. Left filter plates out to dry (shortest duration 40 minutes, longest duration overnight). Sealed bottoms of plates and added 40 pL microscint-20 per well then sealed top. Scanned using 3H-unifilter protocol on Microbeta2. Arranged CPM data and used GraphPad Prism 10 to plot best-fit competitive binding curve for each compound. Converted CPM values from cleaned data to % scale by normalizing each data point to ’Top" CPM value provided by the best-fit curve for each compound. Each competitive assay was done in four technical replicates. Average % data from assays were then combined and plotted using GraphPad Prism 10.
[0447] Competitive Binding Assay (SV2A)
[0448] For experiments described in Example 4, FIGs. 11-14, and Table 8 Prepared 10 mM DMSO stocks of competitor compounds (note: prepared 100 mM stock levetiracetam to account for lower affinity). Diluted competitor compound stocks 1:100 in PBS then completed serial dilution to give row of 12 half-log dilutions of each compound descending from 10 pM. Added 20 pL of each row to 96-well plate in quadruplicate. Diluted3H-UCB-JAttorney Docket No. 047162-7570W01(02947)
[0449] tracer to 6.25 nM (2.5X) in PBS (final concentration 2.5 nM). Added 80 pL tracer to each well of all reaction plates. Thawed control human frontal cortex homogenate (10 mg / mL) and diluted to 4 mg / mL (2X) in PBS (final concentration 0.2 mg / well). Added 100 uL to each well of all reaction plates. Sealed plates and incubated at room temperature at 250 rpm for 90 min. Filtered onto Millipore GFC PEI plates and washed each with -240 mL cold PBS. Left filter plates out to dr ’ (shortest duration overnight, longest duration over weekend). Sealed bottoms of plates and added 50 pL microscint-20 per well then sealed top. Scanned using3H-unifilter protocol on Microbeta2. Arranged CPM data and used GraphPad Prism 9 to plot best-fit competitive binding curve for each compound. Then used outlier detection / removal on Prism analysis with default settings (Q = 1%) one time to generate data with outliers removed. Converted CPM values from cleaned data to % scale by’ normalizing each data point to “Top” CPM value provided by the best-fit curve for each compound. Calculated average % at each concentration for each compound from quadruplicate series of dilutions. The above steps were completed 5 times in independent experiments on different dates, and at least two independent assays were completed for each compound. Average % data from assays were then combined and plotted using GraphPad Prism 9.
[0450] Example 1: Brain Distribution and Kinetics Analysis for [18F]SDM-18
[0451] FIG. 2C and 3B illustrate the summed images from the baseline and blocking scans of [18F]SDM-18 while the corresponding regional brain time-activity curves (TACs) of [18F]SDM-18 as the 1TC model fitted curves are displayed in FIGs. 2A-2B and FIG. 3A. Like its preceding SV2A specific radioligands, [18F]SDM-18 exhibited high uptake and homogenous distribution across the gray matters while uptake in the white matter region is considerably low. [18F]SDM-18 demonstrated fast kinetic and high brain penetrant profile, where maximal standardize uptake value (SUVmax, 16.4) was reached within 15 min postinjection followed by slow washout. Under the baseline conditions, [18F]SDM-18 VT values were observed to be highest in nucleus accumbens, followed by cortex, insula, caudate, thalamus and lowest in centrum semiovale (Tables 2A-2B). Pretreatment with the SV2A-selective Levetiracetam as blocking agent resulted in a significant reduction of [18F]SDM-18 uptake, particularly across the grey matters. Furthermore, displacement experiment with administration of LEV at 90 min led to a reduction in [18F]SDM-18, demonstrating its reversible binding for SV2A.
[0452] Table 2A. Brain regional Ki & VT of [18F]SDM-18 in NHPs - Baseline & Blocking
[0453] Attomey Docket No. 047162-7570W01(02947)
[0454]
[0455] Table 2B. Replicate brain regional Ki & VT of [18F]SDM-18 in NHPs - Baseline
[0456]
[0457] Based on the Lassen plot analysis, [18F]SDM-18 exhibited excellent linear correlations across the gray matters (R2= 0.99) and its SV2A occupancy was calculated to be 83% with LEV at the dose of 30 mg / kg (FIG. 4). This level of receptor occupancy is similar to that measured with other SV2A PET tracers. The estimated VND determined from the x-intercept of Lassen plot was 9.4 mL / cm3, which was higher than [11C]UCB-J (6.27 mL / cm3), [18F]SynVesT-l(4.96 mL / cm3) and [18F]SDM-16 (2.54 mL / cm3), but lower than [11C]UCB-AAttorney Docket No. 047162-7570W01(02947)
[0458] (14.67 mL / cm3). Regional non-displaceable binding potential (BPAD) was calculated based on NND as reference and they ranged from 0.5 to 23.8 (Table 3).
[0459] Table 3. Brain regional BPND of [18F]SDM-18 in NHPs using VND - Baseline & Blocking
[0460]
[0461] To identify the shortest scan duration needed for accurate VT measurement and to indirectly evaluate whether radiometabolites enter the brain, time stability was assessed using 120 minutes of baseline PET data using 1TC model, with acquisition durations truncated from 60 to 120 minutes in 15-minute intervals (FIGs. 5A-5B). The VT values of various brain regions such as cerebellum, putamen, nucleus accumbens, substantia nigra and semiovale, asymptotically approached their terminal values and stabilized within 10% of these values by 75 minutes into the 120-minute scan. During the last 45 minutes, VT values remained nearly unchanged, with an average variation of only 2.7%. The consistent VT measurements from 75 to 120 minutes suggested that radiometabolites did not accumulate significantly in the brain.
[0462] Example 2: Spinal Cord Distribution and Kinetics Analysis using [18F]SDM-18
[0463] TACs of the regional rhesus monkey’s SC, specifically cervical, thoracic and lumbar, were fit with ITCM to estimate the corresponding VT in baseline and blocking scans. The cervical SC region was defined from Cl to C7, thoracic SC region from T8 to T19, and lumbar SC region from L20 to L22. In the baseline scan of healthy rhesus monkey, uptake of [18F]SDM-18 by the spinal cord increased rapidly and SUV peaked at about 15 min with theAttorney Docket No. 047162-7570W01(02947)
[0464] subsequent moderate washout after injection. The highest SUVmax was observed in the cervical SC (6.04). followed by lumbar SC (5.00); the thoracic SC had the lowest SUVmax (3.03). The reversibility and specificity of [18F]SDM-18 binding to SV2Ain the spinal cord (SC) were demonstrated through blocking scans, where pre-treatment with LEV resulted in a significant decrease in [18F]SDM-18 uptake across all regions of the SC after the initial peak uptake. Measured baseline and blocking of VT estimates were found to be the higher in the cervical and lumbar SC regions than the thoracic SC region (Tables 4A-4B). Consequently, these regional VT estimates were plotted using the Lassen Plot to estimate the SV2A occupancy (76%, R2= > 0.99) and VND (5.66 mL / cm3) in full SC (FIG. 7). Regional non-displaceable binding potential (BP / ,) was calculated based on VA© as reference - BPA© of the cervical region, thoracic region and lumbar region ranged from 4.52 to 7.01, 1.71 to 3.97 and 4.58 to 7.97 respectively (Table 5).
[0465] Table 4A. Spinal cord region VT of [18F]SDM-18 in NHPs - Baseline & Blocking
[0466]
[0467] Table 4B. Replicate spinal cord region VT of [18F]SDM-18 in NHPs - Baseline
[0468]
[0469] Attorney Docket No. 047162-7570W01(02947)
[0470]
[0471] Table 5. Regional BPND of [18F]SDM-18 in NHPs using RND - Baseline & Blocking
[0472]
[0473] Attorney Docket No. 047162-7570W01(02947)
[0474]
[0475] Example 3: In vitro assessment of compound binding affinity for SV2A, SV2B, and SV2C
[0476] The disclosure describes experimental evaluation of the binding affinities of certain exemplary compounds of the disclosure against SV2A, SV2B, and SV2C. A competitive binding assay with SV2A / B / C-expressing HEK293 cells was performed, measuring the ability of exemplary compounds of the disclosure (z.e., unlabeled SDM-19 to SDM-28) to displace3H-Padsevonil that is bound to SV2A, SV2B, or SV2C receptors in HEK cells (Tables 6A-6C and Table 7). In certain embodiments, exemplary compounds are selective for SV2A (e.g., SDM-21, SDM-23, SDM-25, and SDM-28). In certain embodiments, SDM-25 has a strong affinity for SV2 receptors, with a K / of 42.92 nM for SV2A. In certain embodiments, the compounds of the disclosure are selective against the SV2B receptor.
[0477] Table 6A. K;values of certain exemplary compounds against SV2A
[0478]
[0479] Table 6B. K, values of certain exemplary compounds against SV2B
[0480]
[0481] Table 6C. K, values of certain exemplary compounds against SV2C
[0482]
[0483] Attorney Docket No. 047162-7570W01(02947)
[0484]
[0485] Table 7. K, values of certain exemplary compounds against SV2A, SV2B, and SV2C
[0486]
[0487] Example 4: In vitro assessment of compound binding affinity for SV2A
[0488] The disclosure describes experimental evaluation of the binding affinities of certain exemplary compounds of the disclosure against the UCB-J binding site on SV2A.
[0489] A competitive binding assay with SV2A-expressing HEK293 cells was performed, measuring the ability' of exemplary compounds of the disclosure and controls (e.g., UCB-J and levetiracetam) to displace3H-Padsevonil that is bound to SV2A receptors in HEK cells (FIGs. 11-12). Certain exemplary compounds of the disclosure demonstrated significantly higher affinity for SV2Athan UCB-J, wherein CZ-A (R) had the highest affinity (z.e., K;< InM) and in general, the (7 )-enantiomer of a given compound had a greater affinity than the corresponding (A)-enantiomer.
[0490] Table 8. SV2A K / for certain exemplary compounds of the disclosure
[0491]
[0492] Attorney Docket No. 047162-7570W01(02947)
[0493]
[0494] “compound had significantly lower K;than UCB-J (95% confidence);bupper threshold for K to be considered significantly lower than K, of UCB-J (95% confidence);cnot able to be calculated.
[0495] Enumerated Embodiments
[0496] The following exemplary’ embodiments are provided, the numbering of which is not to be construed as designating levels of importance:
[0497] Embodiment 1 provides a compound of Formula (I), or a salt, solvate, tautomer, or stereoisomer thereof, or any mixtures thereof:
[0498]
[0499] wherein:
[0500] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl. Br. I, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;
[0501] R2a, R2b, R2c, R2d, and R2eare each independently selected from the group consisting of H and optionally substituted Ci-Ce alky l,
[0502] wherein one of R2band R2cand one of Rlaand Rlfcan combine with the carbon atoms to which they are bound to form an optionally substituted Cs-Cs cvcloalkenvl;
[0503] L is -(optionally substituted C1-C3 alkylenyl)-;
[0504] is selected from the group consisting
[0505]
[0506]
[0507] Attorney Docket No. 047162-7570W01(02947)
[0508] R4a, R4b, R4C, and R4d, if present, are each independently selected from the group consisting of H, F, Cl, Br, I, CN. NO2. N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-Ce alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Cs-Cio and, and optionally substituted C2-C10 heteroaryl,
[0509] wherein one of R4aand R4dand one of R2dand R2ecan combine with the carbon atoms to which they are bound to form an optionally substituted C5-C8 heterocycloalkenyl;
[0510] wherein at least one of R1a. R1b, Rlc, R1d, R1e, R4a, R4b, R4c, and R4d, if present, is18F or a moiety comprising18F, or
[0511] wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C, CRld, CRle, CR2a, C(R2b)(R2c), C(R2d)(R2e), CR4a, CR4b, CR4c, and CR4dcomprises11C;
[0512] wherein the compound is not an18F- or 'hC-isotopologue of a compound selected from the group consisting of:
[0513] (R)-l-((3-fluoropyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
[0514] (R)-l-((3-methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one; (R)-4-(3,5-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0515] (R)-4-(3-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0516] 4-(3,5-difluorophenyl)-l-((2-methyl-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0517] (S)-4-(3,5-difluorophenyl)-l-((2-methyl-lH-imidazol-l-yl)methyl)pyrrolidin-2-one; l-((3-methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
[0518] 4-(3,4-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0519] 4-(3,5-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0520] 4-(4-fluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0521] 4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0522] 4-(3,4-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0523] l-(pyridin-4-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
[0524] l-((3-fluoropyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
[0525] 4-(3-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0526] 4-(3-fluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0527] 4-(4-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0528] l-((4-methylpyridin-3-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
[0529] 4-(3,4-difluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one;
[0530] Attorney Docket No. 047162-7570W01(02947)
[0531] 4-(3,5-difluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one;
[0532] 4-(4-fluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one;
[0533] 4-(3,5-difluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one;
[0534] 4-(3,4-difluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one;
[0535] l-(pyridin-3-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
[0536] l-((4-fluoropyridin-3-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;
[0537] 4-(3-fluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one;
[0538] 4-(3-fluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one; and
[0539] 4-(4-fluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one.
[0540] Embodiment 2 provides the compound of Embodiment 1, wherein L is -CH2-. Embodiment 3 provides the compound of Embodiment 1 or 2, wherein one of the following applies:
[0541] (a) R2a, R2b, R2C, R2d, and R2eare each independently H;
[0542] (b) four of R2a, R2b, R2c, R2d, and R2eare H and one of R2band R2ccombines with Rlaor Rleto form an optionally substituted C3-C8 cycloalkenyl; or
[0543] (c) four of R2a, R2b, R2C, R2d, and R2eare H and one of R2dand R2ecombines with R4aor R4dto form an optionally substituted C3-C8 heterocycloalkyl.
[0544] Embodiment 4 provides the compound of any one of Embodiments 1-3, wherein the compound of formula (I) is selected from the group consisting of:
[0545] (a) a compound of F ormula (la):
[0546]
[0547] wherein in Formula (la):
[0548] Rla, Rlc, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;
[0549] R4a, R4b, and R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalky 1, optionally substituted Ce-Cio ary l, and optionally substituted C2-C10 heteroaryl;
[0550] wherein at least one of Rla. Rlc, Rle, R4a, R4b, and R4c, is18F or a moiety comprisingAttorney Docket No. 047162-7570W01(02947)
[0551] 18F, or
[0552] wherein at least one carbon atom selected from the group consisting of CRla, CRlc. CRle, CR4a, CR4b, and CR4ccomprises11C;
[0553] (b) a compound of Formula (lb):
[0554]
[0555] wherein in Formula (lb):
[0556] Rlaand Rlbare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;
[0557] R4ais selected from the group consisting of H. F, Cl, Br, I, CN, NO2, N3, substituted C1-C6 alkyl, optionally substituted C2-C6 alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cx cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Cs-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0558] R4band R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0559] wherein at least one of Rlb, Rld, R4a, R4b, and R4cis18F or a moiety comprising18F, or wherein at least one carbon atom selected from the group consisting of CRlb, CRld, CR4a, CR4b, and CR4ccomprises11C;
[0560] (c) a compound of F ormula (Ic):
[0561]
[0562] wherein in Formula (Ic):
[0563] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl. Br. I, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;
[0564] Attorney Docket No. 047162-7570W01(02947)
[0565] R4aand R4bare each independently selected from the group consisting of H, F, Cl, Br, I. CN, NO2, N3, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Cg-Cio ary l, and optionally substituted C2-C10 heteroaryl;
[0566] wherein at least one of Rla. Rlb, Rlc, Rld, Rle, R4a, and R4bis18F or a moiety’ comprising18F, or
[0567] wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C, CRld, CRle, CR4a, and CR4bcomprises11C;
[0568] (d) a compound of Formula (Id):
[0569]
[0570] wherein in Formula (Id):
[0571] Rla. Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting ofH, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, andNs;
[0572] R4aand R4dare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, substituted Ci-Ce alkyl, optionally substituted C2-C6 alkyl, optionally substituted Ci-Cg heteroalkyl, optionally substituted C2-C6 alkeny l, optionally substituted C2-G> alkynyl. optionally substituted C?-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Cs-Cio aryl, and optionally substituted C2-C10 heteroaryl:
[0573] R4aand R4bare each independently selected from the group consisting of H, F, Cl, Br, I. CN, NO2, N3, optionally substituted Ci-Cg alkyl, optionally substituted Ci-Cg heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Cg-Cio ary l, and optionally substituted C2-C10 heteroaryl;
[0574] wherein at least one of Rla. Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4dis18F or a moiety comprising18F, or
[0575] wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C, CRld, CRle, CR4a, CR4b, CR4c, and CR4dcomprises11C;
[0576] (e) a compound of Formula (le):
[0577] Attorney Docket No. 047162-7570W01(02947)
[0578]
[0579] wherein in Formula (le):
[0580] Rla, Rlc, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;
[0581] R4a, R4b, R4C, and R4dare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0582] wherein at least one of Rla, Rlc, Rle, R4a, R4b, R4c, and R4dis18F or a moiety comprising18F, or
[0583] wherein at least one carbon atom selected from the group consisting of CRla, CRlc, CRle. CR4a, CR4b, CR4C, and CR4dcomprises11C;
[0584] (f) a compound of F ormul a (If- 1 ) or (If-2):
[0585]
[0586] wherein in Formula (If-1) or (If-2):
[0587] Rla. Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting ofH, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, andNs;
[0588] wherein at least one of Rla, Rlb, Rlc, Rld, and Rleis18F or a moiety comprising18F, or wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CRlc. CRld, and CRlecomprises11C;
[0589] (g) a compound of Formula (Ig):
[0590] Attorney Docket No. 047162-7570W01(02947)
[0591]
[0592] wherein in Formula (Ig):
[0593] R1a, R1b, Rlc, R1d, and Rleare each independently selected from the group consisting of H. F, Cl. Br. I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;
[0594] R4a, R4b, and R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0595] wherein at least one of Rla, Rlb, Rlc, Rld, Rle, R4a, R4b, and R4cis18F or a moiety comprising18F, or
[0596] wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CRlc. CRld, CRle, CR4a, CR4b. and CR4ccomprises11C;
[0597] (h) a compoun d of F ormul a (Ih):
[0598]
[0599] wherein in Formula (Ih):
[0600] Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;
[0601] R4a, R4b, R4C, and R4dare each independently selected from the group consisting of H, F, Cl, Br. I, CN, NO2, Ns, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Cs heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;
[0602] wherein at least one of Rla. Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4dis18F or a moiety comprising18F, or
[0603] wherein at least one carbon atom selected from the group consisting of CRla, CRlb,Attorney Docket No. 047162-7570W01(02947)
[0604] CRlc. CRld, CRle, CR4a, CR4b, CR4c, and CR4dcomprisesnC.
[0605] Embodiment 5 provides the compound of any one of Embodiments 1-4, wherein Rla. Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, and18F.
[0606] Embodiment 6 provides the compound of any one of Embodiments 1-5, wherein one of the following applies:
[0607] (a) Rla, Rlc, and R16are each independently F or18F, and Rlband Rldare each H; and
[0608] (b) Rla, Rlc, and Rleare each H and Rlband Rldare each independently F or18F.
[0609] Embodiment 7 provides the compound of any one of Embodiments 1-6, wherein R3is
[0610]
[0611] Embodiment 8 provides the compound of Embodiment 7. wherein at least one of the following applies:
[0612] (a) R4ais selected from the group consisting of H, Me, / Bu, CN, NO2, CF3, Cl, Br,
[0613]
[0614] (b) R4aand R4bare each independently H, or R4aand R4bcombine with the carbon atoms to which they are bound to form optionally substituted phenyl.
[0615] Embodiment 9 provides the compound of any one of Embodiments 1-6, wherein R3is
[0616]
[0617] Embodiment 10 provides the compound of Embodiment 9, wherein at least one of the following applies:
[0618] (a) R4ais selected from the group consisting of H, Me, -C=CH, -CH2OH, NO2, and I; and
[0619] (b) R4b, R4c, and R4dare each independently H.
[0620] Embodiment 11 provides the compound of any one of Embodiments 1-6, wherein R3Attorney Docket No. 047162-7570W01(02947)
[0621]
[0622] Embodiment 12 provides the compound of Embodiment 11, wherein at least one of the following applies:
[0623] (a) R4ais selected from the group consisting of H and CE-; and
[0624] (b) R4bis H.
[0625] Embodiment 13 provides the compound of any one of Embodiments 1-12, wherein R3is selected from the group consisting of:
[0626]
[0627] Embodiment 14 provides the compound of Embodiment 4, wherein the compound of Formula (T) is selected from the group consisting of Formula (Tg) and Formula (Ih):
[0628]
[0629] wherein at least one of the following applies:
[0630] (a) Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, and18F;
[0631] (b) R4a. R4b, R4C, and R4d, if present, are each independently H.
[0632] Embodiment 15 provides the compound of any one of Embodiments 1-14, wherein the compound is selected from the group consisting of:
[0633] Attorney Docket No. 047162-7570W01(02947)
[0634] l-((2-(tert-butyl)-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one; l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-benzo[d]imidazole-2-carbonitrile:
[0635] l-((lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one;
[0636] 4-(3,5-difluorophenyl)-l-((2-nitro-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0637] l-((2-chloro-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one;
[0638] 4-(3,5-di fluorophenyl)-! -((2-(4-methyl-l, 2, 5-oxadiazol-3-yl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidin-2-one;
[0639] 4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidin-2-one;
[0640] 4-(3,5-difluorophenyl)-l-((3-(trifluoromethyl)-lH-l,2,4-triazol-l-yl)methyl)pyrrolidin-2-one;
[0641] l-((3-methylpyridin-4-yl)methyl)-4-(2,4,6-trifluorophenyl)pyrrolidin-2-one;
[0642] 1 -((2 -bromo- IH-imidazol- 1 -yl)methyl)-4-(3,5 -difluoropheny l)py rrolidin-2-one;
[0643] 4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0644] (R)-4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0645] (S)-4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one; l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;
[0646] (R)-l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;
[0647] (S)-l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;
[0648] 4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0649] (R)-4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0650] (S)-4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;
[0651] 6,8-difluoro-2-((3-rnethylpyridin-4-yl)methyl)-l,2,3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;
[0652] (3aR,9bS)-6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-l,2,3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;
[0653] (3aS,9bR)-6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-1.2.3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;
[0654] Attorney Docket No. 047162-7570W01(02947)
[0655] (9S,9aR)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;
[0656] (9R,9aR)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b] [2,6]naphthyridin-7(5H)-one;
[0657] (9S,9aS)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;
[0658] (9R,9aS)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;
[0659] (R)-4-(3,5-difluorophenyl)-l-((3-iodopyridin-4-yl)methyl)pyrrolidin-2-one;
[0660] (S)-4-(3,5-difluorophenyl)-l-((3-iodopyridin-4-yl)methyl)pyrrolidin-2-one;
[0661] (R)-4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0662] (S)-4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;
[0663] (R)-4-(3,5-difluorophenyl)-l-((3-ethynylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0664] (S)-4-(3,5-difluorophenyl)-l-((3-ethynylpyridin-4-yl)methyl)pyrrolidin-2-one;
[0665] 4-(3,5-difluorophenyl)-l-((3-(hydroxymethyl)pyridin-4-yl)methyl)pyrrolidin-2-one; and
[0666] 4-(3,5-difluorophenyl)-l-((3-nitropyridin-4-yl)methyl)pyrrolidin-2-one; wherein at least one F is18F or at least one C isnC.
[0667] Embodiment 16 provides the compound of any one of Embodiments 1-15, wherein the compound is (R)-4-(3-fluoro-5-(fluoro-18F)phenyl)-l-((2-(trifluoromethyl)-lH-imidazol-1 -yl)methyl)pyrrolidin-2-one.
[0668] Embodiment 17 provides a pharmaceutical composition comprising the compound of any one of Embodiments 1-16 and at least one pharmaceutically acceptable carrier.
[0669] Embodiment 18 provides a method for imaging or detecting a Synaptic Vesicle Protein 2 (SV2) in a subject, the method comprising:
[0670] administering to the subject at least one compound of any one of
[0671] Embodiments 1-16 or the pharmaceutical composition of Embodiment 17; and detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject.
[0672] Embodiment 19 provides a method for quantifying a Synaptic Vesicle Protein 2 (SV2) in a subject, the method comprising:
[0673] administering to the subject at least one compound of any one of
[0674] Embodiments 1-16 or the pharmaceutical composition of Embodiment 17;
[0675] detecting the at least one compound by positron emission tomography (PET)Attorney Docket No. 047162-7570W01(02947)
[0676] in at least one portion of the subject; and
[0677] determining a level of SV2 in the at least one portion of the subject.
[0678] Embodiment 20 provides a method for detecting a disease or disorder involving synaptic disruptions and / or synaptic abnormalities in a subject, the method comprising:
[0679] administering to the subject at least one compound of any one of
[0680] Embodiments 1-16 or the pharmaceutical composition of Embodiment 17;
[0681] detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject;
[0682] determining a level of SV2 in the at least one portion of the subject; and comparing the level of SV2 in the at least one portion of the subject to a SV2 level in a control subject who is not affected by the disease or disorder;
[0683] wherein the disease or disorder is detected in the subject if the SV2 level in the at least one portion of the subject’s body is lower than in the control subject.
[0684] Embodiment 21 provides the method of any one of Embodiments 18-20, wherein the portion of the subject comprises the entire nervous system of the subject.
[0685] Embodiment 22 provides the method of any one of Embodiments 18-21, wherein the portion of the subject comprises at least one selected from the group consisting of the brain of the subject and the spinal cord of the subject.
[0686] Embodiment 23 provides the method of Embodiment 22, wherein at least one of the following applies:
[0687] (a) the portion of the brain comprises at least one selected from the group consisting of amygdala, brainstem, caudate, centrum semiovale, cerebellum, cingulate cortex, frontal cortex, globus pallidus, hippocampus, insula, nucleus accumbens, occipital cortex, pons, putamen, temporal cortex, and thalamus; and
[0688] (b) the portion of the spinal cord comprises at least one selected from the group consisting of the cervical region (e.g, C1-C7), thoracic region (e.g.. T1-T12). and lumbar region (e.g., L1-L5).
[0689] Embodiment 24 provides the method of any one of Embodiments 19 and 21-23, wherein the quantifying permits measurement of synaptic densify.
[0690] Embodiment 25 provides the method of any one of Embodiments 18-24, wherein the SV2 is selected from the group consisting of SV2A. SV2B, and SV2C.
[0691] Embodiment 26 provides the method of any one of Embodiments 20-25, wherein theAttomey Docket No. 047162-7570W01(02947)
[0692] disease or disorder is selected from the group consisting of a neurodegenerative disease or disorder, multiple sclerosis (MS), autism, epilepsy, stroke, traumatic brain injury (TBI), psychiatric disorder, and diabetes.
[0693] Embodiment 27 provides the method of Embodiment 26, wherein the neurodegenerative disease or disorder is selected from the group consisting of Alzheimer’s disease (AD), Parkinson’s disease (PD), frontotemporal dementia, Huntington's disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, dementia with Lewy bodies, and Creutzfeldt-Jakob disease (CJD).
[0694] The terms and expressions employed herein are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the embodiments of the present application. Thus, it should be understood that although the present application describes specific embodiments and optional features, modification and variation of the compositions, methods, and concepts herein disclosed may be resorted to by those of ordinary skill in the art, and that such modifications and variations are considered to be within the scope of embodiments of the present application.
Claims
Attorney Docket No. 047162-7570W01(02947)CLAIMSWhat is claimed is:
1. A compound of Formula (I), or a salt, solvate, tautomer, or stereoisomer thereof, or any mixtures thereof:wherein:Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl. Br. I, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;R2a. R2b, R2C, R2d, and R2eare each independently selected from the group consisting of H and optionally substituted Ci-Ce alkyl,wherein one of R2band R2cand one of Rlaand Rlfcan combine with the carbon atoms to which they are bound to form an optionally substituted Cs-Cx cvcloalkenvl;L is -(optionally substituted C1-C3 alkylenyl)-;R3is selected from the group consistingR4a, R4b, R4C, and R4d, if present, are each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkeny l, optionally substituted C2-Ce alkynyl. optionally substituted C?-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Cs-Cio aryl, and optionally substituted C2-C10 heteroaryl,wherein one of R4aand R4dand one of R2dand R2ecan combine wi th the carbon atoms to which they are bound to form an optionally substituted C5-C8Attomey Docket No. 047162-7570W01(02947)heterocycloalkenyl;wherein at least one of Rla. Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4d. if present, is18F or a moiety comprising18F, orwherein at least one carbon atom selected from the group consisting of CRla, CRlb, CRlc, CRld, CRle, CR2a, C(R2b)(R2c), C(R2d)(R2e), CR4a, CR4b, CR4c, and CR4dcomprises11C;wherein the compound is not an18F- or " C-isolopologue of a compound selected from the group consisting of:(R)-l-((3-fluoropyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;(R)-l-((3-methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;(R)-4-(3,5-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;(R)-4-(3-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((2-methyl-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;(S)-4-(3,5-difluorophenyl)-l-((2-methyl-lH-imidazol-l-yl)methyl)pyrrolidin-2-one; l-((3-methylpyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;4-(3,4-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;4-(4-fluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;4-(3,4-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;l-(pyridin-4-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;l-((3-fluoropyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;4-(3-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;4-(3-fluorophenyl)- 1 -(pyridin-4-ylmethyl)pyrrolidin-2-one;4-(4-fluorophenyl)-l-((3-methylpyridin-4-yl)methyl)pyrrolidin-2-one;l-((4-methylpyridin-3-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;4-(3,4-difluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one;4-(4-fluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one;4-(3,4-difluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one;l-(pyridin-3-ylmethyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;l-((4-fluoropyridin-3-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one;4-(3-fluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one;4-(3-fluorophenyl)-l-(pyridin-3-ylmethyl)pyrrolidin-2-one; andAttorney Docket No. 047162-7570W01(02947)4-(4-fluorophenyl)-l-((4-methylpyridin-3-yl)methyl)pyrrolidin-2-one.
2. The compound of claim 1, wherein L is -CH2-.
3. The compound of claim 1 or 2, wherein one of the following applies:(a) R2a, R2b, R2C, R2d. and R2eare each independently H;(b) four of R2"'. R2b, R2c, R2d. and R2eare H and one of R2band R2ccombines with Rlaor Rleto form an optionally substituted Cs-Cs cycloalkenyl; or(c) four of R2a, R2b, R2C, R2d, and R2eare H and one of R2dand R2ecombines with R4aor R4dto form an optionally substituted C3-C8 heterocycloalkyl.
4. The compound of any one of claims 1-3, wherein the compound of formula (I) is selected from the group consisting of:(a) a compound of Formula (la):wherein in Formula (la):Rla. Rlc, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl. CN, NO2, and N3;R4a, R4b, and R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio ary l, and optionally substituted C2-C10 heteroaryl;wherein at least one of Rla, Rlc, Rle, R4a, R4b, and R4c, is18F or a moiety comprising18F, orwherein at least one carbon atom selected from the group consisting of CRla, CRlc, CRle. CR4a, CR4b, and CR4ccomprises “C;(b) a compound of Formula (lb):Attomey Docket No. 047162-7570W01(02947)wherein in Formula (lb):Rlaand Rlbare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl. CN, NO2, and Ns;R4ais selected from the group consisting of H, F, Cl, Br, 1, CN, NO2, N3, substituted Ci-Ce alkyl, optionally substituted C2-C6 alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C6-C10 aryl, and optionally substituted C2-C10 heteroaryl;R4band R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alky nyl, optionally- substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;wherein at least one of Rlb, Rld, R4a, R4b, and R4cis18F or a moiety comprising18F, or wherein at least one carbon atom selected from the group consisting of CRlb, CRld, CR4a. CR4b, and CR4ccomprises11C;(c) a compoun d of Formul a (Ic):wherein in Formula (Ic):Rla. Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl, Br, T, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;R4aand R4bare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionallyAttorney Docket No. 047162-7570W01(02947)substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted C6-C10 aryl, and optionally substituted C2-C10 heteroaryl;wherein at least one of Rla, Rlb, Rlc, Rld, Rle, R4a, and R4bis18F or a moiety comprising18F, orwherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C. CRld, CRle, CR4a, and CR4bcomprises11C;(d) a compound of Formula (Id):wherein in Formula (Id):Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alky l, CN, NO2, and N3;R4aand R4dare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, substituted Ci-Ce alkyl, optionally substituted C2-C6 alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-Ce alkynyl, optionally substituted Cs-Cs cycloalkyd, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;R4aand R4bare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, Ns, optionally substituted Ci-Ce alkyd, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alky nyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;wherein at least one of Rla, Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4dis18F or a moiety7comprising18F, orwherein at least one carbon atom selected from the group consisting of CRla, CRlb. CR1C. CRld, CRle, CR4a, CR4b, CR4c. and CR4dcomprises11C;(e) a compound of F ormula (le):Attorney Docket No. 047162-7570W01(02947)wherein in Formula (le):Rla, Rlc, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;R4a, R4b, R4C, and R4dare each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;wherein at least one of Rla, Rlc, Rle, R4a, R4b, R4c, and R4dis18F or a moiety comprising18F, orwherein at least one carbon atom selected from the group consisting of CRla, CRlc, CRle. CR4a, CR4b, CR4C, and CR4dcomprises11C;(f) a compound of Formula (If-1) or (If-2):wherein in Formula (If-1) or (If-2):Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alkyl, CN, NO2, and N3;wherein at least one of Rla, Rlb, Rlc, Rld, and Rleis18F or a moiety comprising18F, or wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CRlc. CRld, and CRlecomprises11C;(g) a compound of Formula (Ig):Attomey Docket No. 047162-7570W01(02947)wherein in Formula (Ig):R1a, R1b, Rlc, R1d, and Rleare each independently selected from the group consisting of H. F, Cl. Br. I, optionally substituted Ci-Ce alkyl, CN, NO2, and Ns;R4a, R4b, and R4care each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Ce alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted Cs-Cs cycloalkyl, optionally substituted C2-C8 heterocycloalkyl, optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;wherein at least one of Rla, Rlb, Rlc, Rld, Rle, R4a, R4b, and R4cis18F or a moiety comprising18F, orwherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C. CRld, CRle, CR4a, CR4b. and CR4ccomprises11C;(h) a compound of Formula (Ih):wherein in Formula (Ih):Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, Cl, Br, I, optionally substituted Ci-Ce alky l, CN, NO2, and N3;selected from the group consisting of H, F, Cl, Br, I, CN, NO2, N3, optionally substituted Ci-Cs alkyl, optionally substituted Ci-Ce heteroalkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C3-C8 cycloalkyl, optionally substituted C2-C8 hctcrocycloalk l. optionally substituted Ce-Cio aryl, and optionally substituted C2-C10 heteroaryl;wherein at least one of Rla. Rlb, Rlc, Rld, Rle, R4a, R4b, R4c, and R4dis18F or a moiety comprising18F, orAttorney Docket No. 047162-7570W01(02947)wherein at least one carbon atom selected from the group consisting of CRla, CRlb, CR1C. CRld, CRle, CR4a, CR4b, CR4c. and CR4dcomprisesnC.
5. The compound of any one of claims 1-4, wherein Rla, Rlb, Rlc, Rld, and Rleare each independently selected from the group consisting of H, F, and18F.
6. The compound of any one of claims 1-5. wherein one of the following applies:(a) Rla, Rlc, and Rleare each independently F or18F, and Rlband Rldare each H; and(b) Rla, R1c, and Rleare each H and Rlband R,dare each independently F or18F.
8. The compound of claim 7, wherein at least one of the following applies:(a) R4ais selected from the group consisting of H, Me, / Bu. CN, NO2, CF3, Cl, Br,(b) R4aand R4bare each independently H, or R4aand R4bcombine with the carbon atoms to which they are bound to form optionally substituted phenyl.
9. The compound of any one of claims 1-6, wherein10. The compound of claim 9, wherein at least one of the following applies:(a) R4ais selected from the group consisting of H, Me, -C=CH, -CH2OH, NO2, and I; and(b) R4b, R4C, and R4dare each independently H.Attorney Docket No. 047162-7570W01(02947)11. The compound of any one of claims 1-6, wherein12. The compound of claim 11, wherein at least one of the following applies:(a) R4ais selected from the group consisting of H and CF and(b) R4bis H.
13. The compound of any one of claims 1-12, wherein R3is selected from the group consisting of:
14. The compound of claim 4, wherein the compound of Formula (I) is selected from the group consisting of Formula (Ig) and Formula (Ih):wherein at least one of the following applies:(a) Rla. Rlb, Rlc, Rld. and Rleare each independently selected from the group consisting of H, F, and18F;(b) R4a, R4b, R4C, and R4d, if present, are each independently H.Attomey Docket No. 047162-7570W01(02947)15. The compound of any one of claims 1-14, wherein the compound is selected from the group consisting of:l-((2-(tert-butyl)-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one; l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-benzo[d]imidazole-2-carbonitrile;l-((lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((2-nitro-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;l-((2-chloro-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((2-(4-methyl-l,2,5-oxadiazol-3-yl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-benzo[d]imidazol-l-yl)methyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((3-(trifluoromethyl)-lH-l,2,4-triazol-l-yl)methyl)pyrrolidin-2-one;l-((3-methylpyridin-4-yl)methyl)-4-(2,4,6-trifluorophenyl)pyrrolidin-2-one;l-((2-bromo-lH-imidazol-l-yl)methyl)-4-(3,5-difluorophenyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;(R)-4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;(S)-4-(3,5-difluorophenyl)-l-((2-iodo-lH-imidazol-l-yl)methyl)pyrrolidin-2-one; l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;(R)-l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;(S)-l-((4-(3,5-difluorophenyl)-2-oxopyrrolidin-l-yl)methyl)-lH-imidazole-2-carbonitrile;4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;(R)-4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;(S)-4-(3,5-difluorophenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one;6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-l,2,3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;(3aR,9bS)-6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-l,2,3a,4,5,9b-hexahydro-Attorney Docket No. 047162-7570W01(02947)3H-benzo[e]isoindol-3-one;(3aS,9bR)-6,8-difluoro-2-((3-methylpyridin-4-yl)methyl)-1.2.3a,4,5,9b-hexahydro-3H-benzo[e]isoindol-3-one;(9S,9aR)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;(9R,9aR)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[1.2-b] [2,6]naphthyridin-7(5H)-one;(9S,9aS)-9-(3,5-difluorophenyl)-8,9,9a, 10-tetrahy dropyrrolof 1,2-b] [2,6]naphthyridin-7(5H)-one;(9R,9aS)-9-(3,5-difluorophenyl)-8,9,9a,10-tetrahydropyrrolo[l,2-b][2,6]naphthyridin-7(5H)-one;(R)-4-(3,5-difluorophenyl)-l-((3-iodopyridin-4-yl)methyl)pyrrolidin-2-one;(S)-4-(3,5-difluorophenyl)-l-((3-iodopyridin-4-yl)methyl)pyrrolidin-2-one;(R)-4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;(S)-4-(3,5-difluorophenyl)-l-(pyridin-4-ylmethyl)pyrrolidin-2-one;(R)-4-(3,5-difluorophenyl)-l-((3-ethynylpyridin-4-yl)methyl)pyrrolidin-2-one;(S)-4-(3,5-difluorophenyl)-l-((3-ethynylpyridin-4-yl)methyl)pyrrolidin-2-one;4-(3,5-difluorophenyl)-l-((3-(hydroxymethyl)pyridin-4-yl)methyl)pyrrolidin-2-one; and4-(3,5-difluorophenyl)-l-((3-nitropyridin-4-yl)methyl)pyrrolidin-2-one; wherein at least one F is18F or at least one C isnC.
16. The compound of any one of claims 1-15, wherein the compound is (R)-4-(3-fluoro-5-(fluoro-18F)phenyl)-l-((2-(trifluoromethyl)-lH-imidazol-l-yl)methyl)pyrrolidin-2-one.
17. A pharmaceutical composition comprising the compound of any one of claims 1-16 and at least one pharmaceutically acceptable carrier.
18. A method for imaging or detecting a Synaptic Vesicle Protein 2 (SV2) in a subject, the method comprising:administering to the subject at least one compound of any one of claims 1-16 or the pharmaceutical composition of claim 17; anddetecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject.Attomey Docket No. 047162-7570W01(02947)19. A method for quantifying a Synaptic Vesicle Protein 2 (SV2) in a subject, the method comprising:administering to the subject at least one compound of any one of claims 1-16 or the pharmaceutical composition of claim 17;detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject; anddetermining a level of SV2 in the at least one portion of the subject.
20. A method for detecting a disease or disorder involving synaptic disruptions and / or synaptic abnormalities in a subject, the method comprising:administering to the subject at least one compound of any one of claims 1-16 or the pharmaceutical composition of claim 17;detecting the at least one compound by positron emission tomography (PET) in at least one portion of the subject;determining a level of SV2 in the at least one portion of the subject; and comparing the level of SV2 in the at least one portion of the subject to a SV2 level in a control subject who is not affected by the disease or disorder;wherein the disease or disorder is detected in the subject if the SV2 level in the at least one portion of the subject’s body is lower than in the control subject.
21. The method of any one of claims 18-20, wherein the portion of the subject comprises the entire nervous system of the subject.
22. The method of any one of claims 18-21, wherein the portion of the subject comprises at least one selected from the group consisting of the brain of the subject and the spinal cord of the subject.
23. The method of claim 22, wherein at least one of the following applies:(a) the portion of the brain comprises at least one selected from the group consisting of amygdala, brainstem, caudate, centrum semiovale, cerebellum, cingulate cortex, frontal cortex, globus pallidus, hippocampus, insula, nucleus accumbens, occipital cortex, pons, putamen, temporal cortex, and thalamus;Attorney Docket No. 047162-7570W01(02947)and(b) the portion of the spinal cord comprises at least one selected from the group consisting of the cervical region (e.g, C1-C7), thoracic region (e.g, T1-T12), and lumbar region (e.g, L1-L5).
24. The method of any one of claims 19 and 21-23, wherein the quantifying permits measurement of synaptic density.
25. The method of any one of claims 18-24, wherein the SV2 is selected from the group consisting of SV2A, SV2B, and SV2C.
26. The method of any one of claims 20-25, wherein the disease or disorder is selected from the group consisting of a neurodegenerative disease or disorder, multiple sclerosis (MS), autism, epilepsy, stroke, traumatic brain injury (TBI), psychiatric disorder, and diabetes.
27. The method of claim 26, wherein the neurodegenerative disease or disorder is selected from the group consisting of Alzheimer's disease (AD). Parkinson's disease (PD), frontotemporal dementia, Huntington’s disease, amyotrophic lateral sclerosis (ALS), progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy, dementia with Lewy bodies, and Creutzfeldt-Jakob disease (CJD).
